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Tuberculosis, a highly contagious disease, ranks as the second leading cause of
death from an infectious disease, and remains a major global health problem. In
2013, 9 million new cases were diagnosed and 1.5 million people died worldwide
from tuberculosis. This dissertation aims at developing a new, ultrafine particlebased efficient antibiotic delivery system for the treatment of tuberculosis. The
carrier material to make the rifampicin (RIF)-loaded particles is a low molecular
weight star-shaped polymer produced from glucosamine (molecular core building
unit) and L-lactide (GluN-LLA). Stable particles with a very high 50% drug loading
capacity were made via electrohydrodynamic atomization. Prolonged release
(>14 days) of RIF from these particles is demonstrated. Drug release data fits the
Korsmeyer-Peppas equation, which suggests the occurrence of a modified
diffusion-controlled RIF release mechanism, and is also supported by differential
scanning calorimetry and drug leaching tests. Cytotoxicity tests on
Mycobacterium smegmatis showed that antibiotic-free GluN-LLA and polylactides
(PLA) (reference material) particles did not show any significant anti-bacterial
activity. The minimum inhibitory concentration and minimum bactericidal
concentration values obtained for RIF-loaded particles showed 2- to 4-fold

improvements in the anti-bacterial activity relative to the free drug. Cytotoxicity
tests on macrophages indicated an increment in cell death as particle dose
increased, but was not significantly affected by material type or particle size.
Confocal microscopy was used to track internalization and localization of
particles in the macrophages. GluN-LLA particles led to higher uptakes than the
PLA particles. In addition, after phagocytosis, the GluN-LLA particles stayed in
the cytoplasm and the particles showed a favorable long term drug release effect
in killing intracellular bacteria compared to free RIF. The studies presented and
discussed in this dissertation suggest that these drug carrier materials are
potentially very attractive candidates for the development of high-payload,
sustained-release antibiotic/resorbable polymer particle systems for treating
bacterial lung infections.
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1.1.

Synopsis

This dissertation explores a new, custom-made polymer system as a promising
drug delivery vehicle. Nano- and microparticles for tuberculosis treatment have
been chosen as model system. This highly branched L-lactide grafted
glucosamine (GluN-LLA) oligomer [1] was therefore processed into nano- and
microparticles, resulting in nearly monodisperse particle size distributions. In
addition, particles made from linear low- and high-molecular weight (LMW, and
HMW, respectively) poly (L-lactic acid) (PLA) were produced and studied for
comparison purposes. The most effective first-line anti-tuberculosis drug,
rifampicin (RIF), was encapsulated in these nano- and microparticles via
electrohydrodynamic atomization (EHDA). Particles were prepared from nontoxic or low-toxicity solvent solutions because fully biocompatible drug delivery
systems are ultimately desired. Ethyl acetate, one of the better solvents in this
class, has shown to be very effective for EHDA processing of L-lactide grafted
chitosan [2]. For drug delivery applications, three of the most desirable traits of
these GluN-LLA oligomers are their high solubility in EA, their tunable
hydrophobicity-hydrophilicity balance via control of the length of the lactide
substituents, and their LMWs

One of the most important problems with the current treatment of tuberculosis is
the low patient compliance that causes multidrug-resistant (MDR) tuberculosis,
and usually leads to patient death. A suitable solution to this problem is the
implementation of a system that prolongs the therapeutic effect of one dose. In
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order to demonstrate the sustained release of RIF from the new drug delivery
system, in vitro release studies of RIF were conducted. Cytotoxicity effects of Llactide, and GluN-LLA based particles were tested on macrophages. The
bactericidal activity of encapsulated and free RIF toward the chosen model
microorganism, Mycobacterium smegmatis (M. smegmatis), was evaluated. M.
smegmatis, a non-pathogenic and fast growing specie (generation times of 3-4
hours), shares 2,000 homologs with Mycobacterium tuberculosis (M.
tuberculosis), which makes this microorganism the most accepted model to study
M. tuberculosis [3]. The effects produced by the polymeric matrix were evidenced
by the minimum inhibitory concentration (MIC) and minimum bactericidal
concentration (MBC) values. Intracellular killing of M. smegmatis in
macrophages, caused by RIF loaded particles, was also investigated. Confocal
microscopy was used to determine the internalization and intracellular location of
L-lactide and GluN-LLA based particles containing RIF into macrophages. Finally,
the intracellular killing of M. Smegmatis in alveolar macrophages showed that the
particles are able to maintain a sustained release of RIF into the cells with
release rates affecting the bacteria death rate, further pointing to the potential of
GluN-LLA as a possible new nanoparticle drug carrier for the treatment of
tuberculosis.
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1.2.

Motivation: Why Tuberculosis

Tuberculosis, a highly contagious disease caused by the M. tuberculosis, ranks
as the second leading cause of death from an infectious disease worldwide, after
human immunodeficiency virus (HIV). According to the last report of the World
health Organization (WHO) [4], tuberculosis approximately has infected 9 million
people in 2013. In the same year, 1.5 million people died from this disease,
including 360,000 HIV-positive patients. An estimated 1.1 million (13%) of the
total new cases were HIV-positive.

Even though most cases of tuberculosis and death occur among men (60%) in
their productive life stage, in 2013 there were an estimated 3.3 million new cases
and 510000 deaths among women, and 550 000 infected with 80 000 death
among children. These numbers reflect the high mortality of tuberculosis, which
is unacceptably high given that most deaths are preventable. Tuberculosis can
be cured in 90% of the cases that have access to the medication regimens of
first-line drugs [4].
WHO Global Tuberculosis Report 2014 includes data compiled from 202
countries and territories. It shows that South-East Asia and Western Pacific
Regions represents more than half (56%) of the estimated 9 million new cases in
2013. India and China alone accounted for 24% and, 11% of the total number of
cases, respectively. The African region originated 25% of all cases, and also had
the highest rates of fatal cases.

6
1.2.1. Bacillus Mycobacterium Tuberculosis

M. tuberculosis typically affects the lungs (pulmonary tuberculosis), but can affect
other sites as well (extra-pulmonary disease), and is transmitted by aerosols from
the lungs of coughing infected individuals. Exposure to these bacteria does not
always translate into infection. It is estimated that bacteria is cleared by a robust
innate immune response in 50% of the individuals exposed to M.tuberculosis. As
for the rest of the infected population, only 5% progress toward the development
of active tuberculosis, and the remaining 95% control the infection throughout
their lives (latent tuberculosis) [5]. About one-third of the world’s population
(approximately 2 billion people) has latent tuberculosis, which progresses to the
active disease when a patient’s immune system is compromised by say, HIV
infection, old age, immunosuppressive drug treatment, or re-infection [4–7].
M. tuberculosis is a relatively slow-growing microorganism with a generation time
of 24 hours. Infection is spread via airborne dissemination of aerosolized bacteria
containing droplet nuclei of 1-5 µm [7]. M. tuberculosis bacteria that gain access
to a new host via inhaled air can begin the replication process inside the alveolar
macrophages after 2-3 weeks of infection. Macrophages usually ingest and trap
pathogens in a phagosome, which is then subject to a series of fusion and fission
events with the endocytic pathways that end in a phagosome-lysosome fusion.
This process is known as phagosome maturation, in which phagosomes acquire
the antimicrobial tools to eliminate the pathogen. These killing mechanisms
include acidification (pH<5), production of antimicrobial peptides, generation of
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reactive oxygen and nitrogen species, and degradative enzymes such as
cathepsins. However, M. tuberculosis is able to modulate pH-reducing events in
a maturing phagosome, which can result in a more basic phagolysomal pH, thus
enhancing bacteria survival and facilitating dormancy. The general view is that M.
tuberculosis arrests phagosomal maturation by inhibition of both lysosomal fusion
and reduction of recruitment of vacuolar H+-ATPases. These manipulations over
the normal course of phagosomal maturation result in a modest drop of
intrasomal pH, which avoid bacteria killing and favors its replication [5,8].

1.2.2.

Current Chemotherapy against Tuberculosis

Mortality rates of tuberculosis fall between 50 to 80% in untreated patients and
drop to 5% for individuals receiving an active therapy [4,7]. The current
treatment, tuberculosis chemotherapy, requires six months of an extensive drug
regimen of RIF, isoniazid (INH), pyrazinamide (PYZ), and ethambutol [7]. The
treatment comprises the following two stages: (1) an intensive 2-month daily use
of the four drugs mentioned before followed by (2) a 4-month daily administration
of RIF and INH. This long and intensive treatment is one of the main causes for
low patient compliance, and failure to adhere to the prescribed drug regime has
resulted in the significant emergence of drug resistant strains of M. tuberculosis.
Multidrug-resistant (MDR) tuberculosis has become a complex problem due to
the recent proliferation of such strains. Treatment of MDR tuberculosis takes
longer than conventional treatment modalities (WHO recommends 20 months),
and requires more expensive and toxic drugs with lower success rates [4,9,10].
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1.2.3.

Rifampicin (RIF)

Rifampicin (Figure 1.1, formula: C43H58N4O12) is a semisynthetic derivative of the
rifamycins, which are a class of antibiotics derived from fermentation products of
Nocardia mediterranei. RIF possesses a unique mechanism of action that
confers it a high level of antibacterial activity and it is based on the inhibition of
bacterial RNA polymerase. By this action, RIF stops bacterial growth in a wide
range of bacteria, including mycobacterium tuberculosis [11].

Figure 1.1 – Rifampicin Chemical Structure
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1.2.4.

Need for New Approaches to Combat the Disease

Usually, patients fail to take the prescribed medications with adequate regularity
and duration. In spite of the fact that current anti-tuberculosis chemotherapy
treatment is highly effective in killing M tuberculosis, it involves a multidrug
regimen where patients have to take a significant number of pills daily (up to
eight at one time) for a long time. This is the main reason for patient noncompliance, but the appearance of side effects is also cited. With the current
treatments, only a small fraction of the dosed antibiotics reach the target area,
mainly because its first-pass metabolism decreases the amount of drug that gets
into the blood stream. As a consequence, to achieve therapeutic levels large
doses of drugs are normally needed, and the probability of patients experiencing
side effects increases [12]. Hepatotoxicity, the most common side effects of antituberculosis drugs, generally leads to treatment withdrawal [7,13]. These
difficulties associated with patient non-compliance are the main driver behind
new research aimed at exploring new drug administration concepts. Multiple new
drugs and vaccines are in the pipeline or are being investigated nowadays, but
neither route guarantees success [14], nor do they go against conventional
treatment paradigms.

An alternative strategy to current treatment approaches is to encapsulate antituberculosis drugs in nano- or microparticles made from biodegradable polymers.
For instance, a very effective treatment should target alveolar macrophages
where M. tuberculosis is harboring via suppression of the phagosome-lysosome
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fusion process [15]. Since alveolar macrophages are one of the first lines of
defense against entry of external particles including microbial invasion,
macrophages targeting is generally accomplished even without any specific
tailoring of the particles [16]. Therefore, in this work, drug delivery systems
comprising RIF-loaded nano- and microparticles made from two biodegradable
polymers (GluN-LLA and PLA) are presented as a potentially new strategy to
treat tuberculosis.

1.3.

Background

This section presents basic background material which will be relevant to more
specific discussions in subsequent chapters.

1.3.1. Particulate Drug Delivery Systems
Generally, conventional drugs are low molecular weight substances capable of
crossing body barriers and accessing numerous cell types and subcellular
organelles. Although this aspect represents a desired feature for the treatment of
diseases, it also implies an indiscriminate distribution of the drug to an
uncontrollable extent of the body. As a consequence of this drug ‘dilution’ in the
body, higher doses of the therapeutic agent are required for a satisfactory
pharmacological response, which usually carry undesired side effects on the
patient. Rapid renal clearance of drugs requires frequent administration,
threatening, especially in long-term treatments, the compliance of the patients
[17]. Compliance is crucial for curing tuberculosis. Standard multi-antibiotic
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treatment results in systemic delivery of the drugs throughout the body; drugs are
rapidly detoxified and/or excreted, and daily doses are required. RIF, INH and
PYZ, first-line anti-tuberculosis drugs, are metabolized by the liver and induce
hepatotoxicity. This adverse effect is of primary concern, because it often
requires changes in the treatment [13,16].

Controlled-release drug delivery systems are designed to provide adequate
doses of therapeutic agents for a relatively long period of time, to the proper
location, in an effective manner to increase compliance and minimize side effects
[18]. These systems employ devices that are capable of releasing drugs by
reproducible and predictable kinetics. Biodegradable polymeric nano- and
microparticles are among the most investigated types of devices as drug delivery
vehicles. Some of their advantages are, (1) drug release rates can be tailored to
the need of a specific application, (2) protection of the drug from degradation and
clearance, especially proteins, with lower required doses, (3) improved patient
comfort and compliance by decreasing the frequency of doses, for example,
sometimes even from daily to weekly doses, and (4) localized, targeted delivery
of the drug to minimize side effects [17–19]. Controlled-release particle
formulations that maintain a constant level (zero-order release kinetics) of a drug
for long periods of time i.e, effectively prolonging the therapeutic effect of one
dose, is the ultimate long-term goal in developing the drug carrier systems
presented in this dissertation. These formulations are often referred to as
“sustained release”, or “prolonged release formulations” [20]. One critical concern
with orally administering RIF is its bioavailability in the acidic environment of the
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stomach. RIF displays decomposition rates between 8.5 to 50% in the
corresponding gastric time for most treatment modalities in humans (~15 to 105 ±
45 min) [21,22]. The entrapment of RIF inside ultrafine particles serves not only
as a means to develop a slow-release reservoir system, but also as protection
from degradation, which in principle solves the RIF bioavailability issue [7].

1.3.1.1.

Drug release mechanisms and mathematical modeling

Several factors affect release rates in nano- and microparticles, such as mode of
drug entrapment, polymer type and its molecular weight, copolymer
compositions, polymer matrix-drug interactions, excipients, particle geometry,
and physicochemical and biological properties of the active and carrier
ingredients, among others [17,18,23,24]. Drugs can be encapsulated inside a
“core” or reservoir surrounded by a thin polymer “shell”, or can be uniformly
dispersed or dissolved in the polymer matrix. These two different drug
entrapment modalities are usually defined by the type of particle being designed
for, i.e., core-shell or solid particle. The polymer type and its molecular weight are
governing elements affecting the mechanism by which the drug is released from
the particles. These factors strongly influence particle characteristics like
degradation rate, swellability and polymer matrix interaction with the drug [24]. In
this dissertation, RIF was dissolved in GluN-LLA and PLA matrix, and four
particulate drug delivery systems were produced. Drug release studies and
mathematical modeling from this data are used to assess the relative importance
of drug-matrix interactions.
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Numerous mathematical models that predict polymer drug delivery behavior have
been reported over the last few decades [25]. The classic Ritger and Peppas
equation Mt/M∞ = ktn [26] is a simple exponential form that can be used to fit drug
release kinetic data. In the equation, Mt/M∞ is the drug cumulative release
percentage at time (t), k is the rate constant, and n is the so-called diffusional
exponent. Both n and k are determined by the principles governing diffusion,
degradation, relaxation, matrix-drug interaction, and geometry of the drug
delivery system. Fickian-type diffusion of a drug for example, is driven by a
chemical potential gradient. Relaxational release refers to systems possessing a
swellable matrix, and is mostly hydrophilic polymers. In this particular case, the
carrier’s polymer chains “relax” upon contact with water or biological fluids, and
this facilitates drug delivery by increasing its mobility across the matrix.

In the pharmaceutical field, data from drug release experiments are generally
fitted to the Ritger and Peppas equation, and the obtained n value is used to
propose a drug release mechanism [25]. For spherical particles, a pure Fickian
diffusion controlled-release system is described by n=0.43, while n=0.85 is
related to swelling-controlled drug delivery mechanism. Values of n between
these two numbers represent drug release systems controlled by both diffusional
mass transport, and chain relaxation. The case of n=0 correspond to a zero-order
drug release process, and is related to systems displaying pure biodegradationcontrolled behavior, where drugs are strongly entrapped (e.g. covalently bonded)
within the polymer matrix [27]. Values of n between 0 and 0.43 represent an
overlap of drug-matrix interaction and diffusion mass transport mechanisms [27].
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Since Ritger and Peppas equation does not fit data well in cases where high
degradation rates occur, other mathematical models may be adopted.
Biodegradable polymers are widely used in the design of nano- and
microparticles as controlled drug delivery systems. Polymer degradation routes
can be divided into two different categories: bulk-eroding and surface-eroding
degradable systems. Numerous mathematical models that apply to degradable
systems can be found in the literature [19,28].

For the sake of illustration, one can picture a model solid nanoparticle having the
drug uniformly dispersed in a degradable copolymer matrix, and the different
possible mechanisms of controlled drug delivery systems. Case 1: the rate of
degradation is slow enough for the particle to be taken as non-degradable during
the release period, and the matrix does not either swell or presents no important
interaction with the drug. This drug delivery system would probably be controlled
by pure Fickian diffusion (n=0.43) [26]. Case 2: swellability effects in the polymer
matrix are large enough that when water diffuses into the particle, polymer chains
relax and drug is released by a swelling-controlled process (n=0.85) [29]. Case 3:
very strong drug-matrix interactions or polymer-drug conjugates are formed. Drug
release depends only on biodegradation or chemical erosion to free the drug
from the particle (n=0). These three situations represent the three extreme cases
of drug delivery i.e., a process governed by one single phenomenon (diffusion,
relaxation and degradation). Systems that are controlled by a combination of two
or more phenomena are all too common, e.g. diffusion and relaxation coupling
(0.43<n<0.85) [30]. Values of n between zero and 0.43 are generally taken as
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indicative of diffusion and matrix-drug interaction mechanisms being present.
Matrix-drug interactions are most likely responsible for strong delaying effects in
observed drug release profiles. In this last case, the polymer matrix does not
undergo swelling, and the carrier’s degradation rate is also not an important
factor.

In this dissertation, GluN-LLA nano- and microparticles particles have been
produced, with the goal of functioning as controlled-release drug delivery
systems. Since their biodegradation rates were relatively modest (see Chapter
3), it was not considered to be an important factor in the modeling of the release
process. Due to GluN-LLA particles containing a larger proportion of L-lactide
molecular building blocks relative to their glucosamine core unit, this copolymer
was a priori viewed as a good non-swelling system. Therefore, the Ritger and
Peppas equation was viewed as a viable candidate to model the drug release
profiles.

Frequently, especially for prolonged release products, there are three basic
stages in a time-release profile: (1) initial burst of drug release, taking place
during the first few hours, followed by a (2) slow diffusion-controlled release, and
finally, a (3) phase where drug is released faster as a consequence of
degradation start playing a pivotal role. Burst release is usually linked to drug
diffusion from the outermost layers of the particles. In some cases, degradation
can be controlled to a good extent by varying the ratio of the monomeric building
blocks in copolymers. For example, poly(lactic-co-glycolic) (PLGA) degradation
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rates can be increased by having higher glycolic acid contents [20]. Despite the
observed differences between drug release phases one and two (chapter 3), RIF
release profiles from GluN-LLA and PLA particulate systems showed no phase
three during the observation period (~14 days). This also suggests a slow
degradation rate.

1.3.1.2.

Drug Delivery Approaches for Tuberculosis Treatment

As mentioned in Section 1.2, tuberculosis chemotherapy requires the
administration of a multi-drug regimen over a long period of time. Low patient
compliance is the main reason for treatment failure, which in turn frequently
causes MDR tuberculosis and/or patient death. In order to improve compliance,
minimize toxicity and to increment RIF bioavailability in tuberculosis treatment,
efforts have been made to develop drug delivery systems composed of nanoand microparticles.

Various drug carriers derived or purified from natural sources such as chitosan
[31], alginate [32,33], gelatin [34], fatty acids (Pheroid technology) [35] and
synthetic encapsulants, such as poly(lactide-co-glycolide) (PLGA) and poly-D,Llactide (PDLLA) have been used in anti-tuberculosis drug encapsulation. RIF is
one of the first-line antibiotics being used in treatments of tuberculosis, and is
usually employed when investigating new particulate systems. A review of the
recent literature on RIF controlled release systems reveals that the most popular
drug carriers still belong to PLGA family [12,36–47]. For studying a subcutaneous
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injection approach, Dutt et al. [44] produced PLGA microparticles containing RIF
and INH by the double emulsion evaporation technique and particles size was
11.75 µm and 11.64 µm respectively. The particles were administered in a single
dose subcutaneously to mice; the microparticles sustained a therapeutic release
of the drugs for 7 and 6 weeks for INH and RIF respectively. As an observation,
authors showed that particles with diameter > 10 µm remained at the site of
injection, forming a depot where drugs were released via diffusion processes.
Such a depot can release drugs over several weeks, while the same dose of free
drugs were present in vivo only for 24 hours. It needs to be indicated however,
that subcutaneous and intravenous routes of administration involve injections,
which in turn lead to additional patient pain and discomfort. This tends to favor
the development of oral and inhalation drug delivery systems as being more
convenient to patients and as a natural result, more research has been reported
for the oral and inhalation drug administration routes.

As an oral formulation strategy, Ain et al. [45] used a double emulsion technique
to encapsulate RIF, INH and PYZ in PLGA microparticles with a size range
distribution between 1.1-2.2 µm. These particles were administrated orally in
mice, and drug concentrations achieved via use of microparticles were compared
with those resulting from use of the free drug. In all cases, encapsulated drugs
remained present in circulation for up to 72 hrs after dosage, while administration
of free drugs led to their elimination within 24 hrs. Pandey et al. [47] prepared
RIF, INH, PYZ loaded PLGA nanoparticles by the multiple emulsion technique
obtaining a particle size range between 186-290 nm, with a drug encapsulation
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efficiency of 56.9±2.7 %. Drug levels in plasma reached therapeutic values for 68 days and for up to 11 days in the lungs with a single dose administration to
guinea pigs. Even though use of drug-loaded microparticles leads to lower doses
and lower administration frequency via the oral route than when the free drugs
are administered, first-pass metabolism is still a concern. This phenomenon (also
known as first-pass elimination or presystemic metabolism) refers to the drug
fraction that is metabolized after its administration, and before it is effectively
utilized at the desired therapeutic site. The primary organ involved in first-pass
metabolism of an orally administered drug is the liver, other areas with less
impact on first-pass metabolism are the gastrointestinal tract, blood, vascular
endothelium and lungs [48].

In the case of pulmonary drug delivery, inhalation therapy has the added
advantage of being capable of releasing the anti-tuberculosis drugs right at the
main site of infection, where alveolar macrophages harbor M. tuberculosis
bacteria inside the phagosomes. In addition, inhalation therapy has the inherent
benefit of chiefly bypassing first-pass metabolism, thereby allowing elevated local
concentrations of the drug where it is most needed, and without requiring high
drug concentrations in circulation. This, in turn, reduces systemic toxicity risks.
Via the inhalation route, it is also possible to achieve systemic therapeutic
concentration of the drugs [7,49]. This is important in that tuberculosis is a
systemic disease that primary affects the lugs, but can also affect other areas as
well such as the liver, kidney and spleens. There are a considerable number of
publications in the open literature that propose formulation of anti-tubercular
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drugs into nano- and microparticles for pulmonary delivery. In spite of the fact
that first-line drugs are the ones that are predominantly used, other second- and
third-line anti-tubercular drugs have been investigated [7,49,50]. RIF alone has
been encapsulated in PLGA microparticles mostly by means of two techniques:
double emulsion [46,51,52] and spray drying [12,52,53]. RIF has been also
encapsulated in combination with other first-line anti-tuberculosis antibiotics,
especially with INH and PYZ [47,51,54]. Table 1 shows what are believed to be
the most relevant published research in RIF-loaded microparticles made out of
synthetic polymers for pulmonary delivery treatment of tuberculosis. As it can be
observed, values for drug loading (DL) capacity vary between 10-30% for PLGA
and 8-16% and for PLA microparticles. Other natural materials such as chitosan
[31], alginate [32], and gelatin [34] were also employed to encapsulate RIF, and
showed DL of 8.9-46.3%, 25-37%, and 42%, respectively. In this dissertation,
stable RIF-loaded particles presenting DL of 50% were produced by the
electrospray technique. This superior characteristic of GluN-LLA systems is
attributed to the fabrication method (next section), and the physicochemical
properties of the polymer that promote high drug-polymer interactions (Chapter
3).
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Table 1.1 – Rifampicin -loaded particles made of synthetic polymers for
pulmonary delivery treatment of tuberculosis. Particle diameter (Pd), drug loading
(DL)

Ref.

Manufacturing

Pd

method

(µm)

Emulsion
[52]

[12]

3.456.84

Carrier

DL
(%)

PLGA

20

In vitro release 34% in 24hrs

Spray drying

2.76

PLGA

30

In vitro release 74% in 24hrs

Spray drying

2.87

PLGA

30

In vitro release 52% in 24hrs

1.5
[42]

Drug release and comments

Spray drying

and

Phagocytosis dependency on
PLGA

10

3.5

particle size: 80% uptake 3.5
µm microparticles.
Drug release accelerated by

[41]

Emulsion

2.84

PLGA

10

50-90% in 24 hrs)
Supercritical

[55]

pulmonary surfactant (release

anti-solvent

Optimization of fabrication
3.29

PLA

8-16 method conditions. Release

process

30-100 % in 24 hrs)
Intracellular RIF from particles
containing 0.25 and 2.5 μg

Spray drying
[53]

2.76

PLGA

-

RIF/mL were 2 and 10 times
higher than 5 μg/mL of free
RIF – ~50 % intracellular
killing after 7 days
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1.3.1.3.

Electrohydrodynamics as a Tool for Fabricating Drug Delivery
Carriers

Over the past few decades, there has been a growing interest in developing
biodegradable nano- and microparticles as drug delivery systems. There are
several methods for making ultrafine particles, such as emulsificationevaporation, salting-out/emulsification, nanoprecipitation, ionic gelation,
coacervation, spray-drying and electrospray, among others [56–58]. As it can be
deduced from Table 1.1, for pulmonary delivery of RIF, the emulsion/solvent
evaporation and spray-drying methods are the ones that are most frequently
used.

Solvent evaporation and emulsion-based methods are commonly used to
prepare ultrafine particles, especially at lab scale. The emulsification/solvent
evaporation technique involves emulsification of a dispersed phase in which the
polymeric matrix and the drug have been dissolved or dispersed. The two phases
are emulsified at high sheer rates, until the solvent evaporates and particles are
formed [50]. RIF-loaded PLGA microparticles of diameters in the 3.5 to 6.5 µm
range for pulmonary delivery were prepared using this method by O’Hara and
Hickey [52]. Methylene chloride and polyvinyl alcohol (PVA) were used as
dispersant and emulsifier, respectively. The two phases were mixed at 5000 rpm
for 45 min, and particles were collected by filtration. However, emulsion-based
methods possess a number of important disadvantages have limited their
application. Large-scale production poses great technological difficulties, and is
cost-prohibitive. Particle size distributions are usually broad, and standard
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deviations of 50% are not uncommon. This, in turn, makes consistent drug
release profiles difficult to obtain. Drug exposure to organic solvents, high
temperatures and high shear stresses could potentially decrease, or in some
cases eliminate drug viability, especially with delicate biomacromolecules. In
addition, toxic compounds such as some of the additives and/or surfactants used
in this process, require time-consuming steps for their removal [18].

The spray-drying method has grown in popularity to manufacture respirable
particles due to the variety of materials that can be employed with it, and the
range of sizes (microparticles) that can be obtained. This technique is a one-step
process that produces particles from the atomization of a liquid feed. The
droplets from the spray are dried to form solid particles. As shown in Table 1.1,
RIF-loaded PLGA microparticles have been successfully produced by this
technique [50,59]. However, this particle manufacturing process requires high
capital costs, and bulky equipment that is expensive to maintain. Process scaleis still an important challenge with this method. This is rooted in the low thermal
efficiency of the system i.e., the large volume of heated air with low or no contact
with particles [59].

Electrospray, one of the two popular electrohydrodynamic (EHD) techniques, is a
facile, inexpensive fabrication method that uses an electric field gradient to
create solid or hollow particles. EHD principles, modes of operation, and
instruments for small-scale production are well-established and well described in
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the literature (see figure 1.3) [57,58,60–63]. The basic, lab-scale ES system
consists of (1) a high voltage power supply, (2) a spinneret, and (3) a grounded
collector plate. Electrical forces counter the effect of surface tension of the
polymer solution extruded from the spinneret. The net result is the formation of a
quasi-conical meniscus at the exit orifice. Typically, from the Taylor cone’s apex
an electrified liquid jet is ejected and breaks down into droplets. Particles are
generally formed depending on where, during the “time of flight” of the electrified
droplets to the collector electrode, solidification due to solvent evaporation occurs
[57,58,60–63].

Figure 1.3 - Basic electrospray apparatus

Chakraborty et al. discussed the physics involving electrospray [58]. Important
phenomena governing electrospray are electrodynamic, gravity, inertia, and drag
forces. Electrodynamic forces are proportional to the induced electric field on the

24
charged nozzle and flying droplets. Drag forces depend on the jet velocity, and
the viscosity of the gas surrounding the nozzle. The following scaling relation has
been developed:
𝑎𝜌

𝑄 𝑎𝑄 𝜀0𝑎𝜀 𝜌1
𝑑=𝛼
𝑎𝛾 , (equation 1.1)
𝜎1𝑎𝜎 𝛾1
Where, d is droplet diameter, Q is the volume flow rate, ε0 is the permittivity of
free space, ρ1 is liquid density, σ1 is liquid surface tension, γ1 is liquid bulk
conductivity, and α is a coefficient that depends on liquid permittivity. These and
other characteristic parameters and coefficients have been studied by different
authors. Typical values are in table 1.2:

Table 1.2. Coefficient for equation 1.1 to determine droplet size
Authors

aQ

Fernandez de la Mora and Loscertales [64]

aε

aρ

aσ

aγ

1/3 1/3

0

0

1/3

Gañán Calvo [65] and Gañan Calvo et al. [66]

½

1/6

1/6

1/6

1/6

Hartman et al. [67]

½

1/6

1/6

1/6

1/6

Two principal modes of electrospray operation for making ultrafine particles have
become popular over the last two decades: monoaxial and coaxial fluid delivery.
Monoaxial electrospray utilizes a one-nozzle, one-liquid delivery arrangement,
and creates solid particles with matrix-encapsulated drugs. Coaxial electrospray
uses an emitter based on two coaxial nozzles to make core-shell particles.

25
Monoaxial electrospray was used in this dissertation to produce RIF-loaded solid
GluN-LLA and PLA nano- and microparticles. In this case, RIF was embedded in
the particles through dissolving it in the polymer solution precursor.

The electrospray method has several advantages in the preparation of nano- and
microparticles over other methods. Residual charges on the particles and drying
effect of EHD “atomization” assure little or no aggregation on solvent
evaporation. The absence of high-shear forces such as those present in stirring
or sonication protects drugs with fragile molecular structures. Besides high
loading levels and high encapsulation efficiency, electrospray achieves uniform
dispersion of the drug in the polymeric matrix if so desired. Also, EHD methods
are easy operable at a laboratory scale [58].

Thus, among the various ultrafine particle preparation methods currently
available [56–58], electrohydrodynamic atomization (EHDA) stands out for its
simplicity and general applicability [57,58]. The EHDA production of particles from
many synthetic and naturally occurring polymeric systems as drug carriers has
been demonstrated in the past [58,61,68]. It has also been shown recently that
both particle size and morphology can be controlled in a relatively simple manner
with this method [69].

Papers on EHDA processing of polylactides (PLAs) for this particular application
are scarce [70], and very few studies reporting on the preparation of MP made
from PLA polymers loaded with RIF using spray drying techniques [55,71,72].
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Bain and co-workers [71] produced RIF loaded PDLLA microparticles from a
series of mixtures of low (2 kDa) and modestly low (9 kDa) molecular weights
(MWs). The RIF release rates were strongly affected by relatively small changes
in the mixture composition, and increased with increasing content of the low MW
(LMW) fraction. Celikkaya and co-workers [72] prepared a series of
microparticles using PDLLA with MWs in the 9,7-23 kDa range, obtaining a
maximum drug loading of only 10%. Moreover, a rather “permanent” RIF
entrapment within the polymer matrix occurred. This, coupled with the slow
PDLLA degradation kinetics, resulted in only a 20-30% release of the initial drug
payload. Similarly, Coowanitwong and collaborators [73] found incomplete RIF
release during the first 24 hours from microparticles prepared using HMW PLA
(75-125 kDa) and PLGA (40-65 kDa). It is worth mentioning that among the
polylactide polymer family members, PDLLA is favored for drug delivery
applications owing to its disordered chain structure, which in turn translates into a
purely amorphous material [43].
1.3.1.4.

Drug Delivery system: Cost analysis

An efficient delivery vehicle should have the potential to reduce dosages and
side effects related to unintended dispersion of the drug through the body.
Delivering the correct dosage to the proper location is important not just from
safety, convenience and efficacy standpoints, but also from a cost-cutting
perspective [74] . The implementation of RIF-loaded GluN-LLA ultrafine particles
as drug delivery systems for the treatment of tuberculosis would potentially
decrease the conventional therapy costs by reducing the amount of drug used
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during the treatment. As mentioned before, the RIF-loaded particles presented in
this dissertation are eventually intended to be administrated by the inhalation
route, and thus to effectively target the M. tuberculosis harboring inside the
alveolar macrophages. The immediate significance of this targeting is two-fold: to
achieve drug dose reduction, and to potentially decrease the overall treatment
time. A reduction in the amount of drug used for adequate treatment would
translate into a substantial decrease in costs when compared to conventional
treatment modalities. In addition to reduction in the occurrence and frequency of
side effects, the fact that GluN-LLA particles deliver RIF for a long period of time
(~14 days, chapter 3) would decrease the frequency of drug administration, and
as a consequence, patients would likely be more compliant to treatment. High
levels of adherence to treatment will also stop the development of MDR
tuberculosis (and decrease the use more expensive and toxic drugs), and
ultimately reduce healthcare costs.

Even when GluN-LLA synthesis and particle processing are cost-effective and
easily scalable when compared with other techniques (section 1.3.1.3), the final
drug delivery product, which is envisioned as dry powder inhaler, will eventually
cost more than pure RIF on a weight of drug basis. However, the cost cutting
factors in this case will be efficacy enhancements, patience compliance and
shorter treatment duration [75]. In this regard Owens et al. published an
evaluation of the cost-effectiveness of a novel first-line treatment with
hypothetical regimens of equal efficacy, higher cost, and shorter duration than the
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conventional 6 months treatment. In their study, these authors conclude that the
more novel treatment approach effectively reduced treatment costs.
This doctoral dissertation proposes a pulmonary RIF delivery system capable to
cure tuberculosis and effectively reduce the cost of treatment. This hypothesis
would ultimately have to be tested by a comprehensive cost-effectiveness study.
1.3.2. Glucosamine L-lactide (GluN-LLA)
GluN-LLA, a new biocompatible oligomer is produced by a ‘one-spot’ synthesis
route, where L-lactide chains are grown onto glucosamine molecules via –OH
groups. This polymer and the production method were designed and first
characterized by Skotak and Larsen [1] at the University of Nebraska – Lincoln in
2010. These authors thoroughly characterized this polymer system via 1H and
13

C nuclear magnetic resonance (NMR), Fourier transform infrared (FTIR), and

UV-visible spectroscopies, electrospray ionization mass spectrometry (ESI-MS),
gel permeation chromatography (GPC), and differential scanning calorimetry
(DSC). Conveniently, this polymerization method does not employ the
conventional organometallic tin catalyst for the lactone ring-opening
polymerization process, which eliminates the presence of cytotoxic impurities in
the product. The synthesis of L-lactide grafted chitosan [2] was also successfully
achieved by using this methodology, which demonstrates the simplicity and
flexibility for grafting lactone chains onto simple aminosugars and sugar rings.
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GluN-LLA (figure 1.2) is a low molecular weight star-shaped biocompatible and
biodegradable polymer. By controlling the initial LLA-to-core molecule molar
ratios it is possible to control the length of the lactide substituents, and
consequently this GluN-LLA holds the capability of having a tunable
hydrophobicity-hydrophilicity balance. In this dissertation, GluN-LLA 1:32 with a
degree of substitution of 3.8/4 and lactate side length of ~11 monomers was used
to produce RIF-loaded and drug-free nano- and microparticles (Table 1 in ref [1]).

The fact that the building blocks of two of the most well-known biocompatible
polymers (chitosan and PLA) have been used to produce one LMW co-polymer,
a priori positions GluN-LLA as a potential material for biomedical applications.
Moreover, the hypotheses of biocompatibility and biodegradability are tested in
this dissertation. This thesis is thus the first documented implementation of a
GluN-LLA oligomer as drug delivery system in particular, and biomedical
applications in general. In this work, biocompatibility of the GluN-LLA nano- and
microparticles is assessed via cell viability in Chapter 3.

30

Figure 1.2. Glucosamine-L-lactide oligomer

1.3.3. Antimicrobial Susceptibility Test
Antimicrobial susceptibility testing is important to determine susceptibility of
species that are considered clinically significant in antimicrobial agents, or to
detect resistance in individual bacterial isolates. The Clinical and Laboratory
Standards Institute (CLSI) develops and provides standardized methods to
perform antimicrobial susceptibility tests for several groups of bacteria. For
instance, CLSI recommends the standard broth microdilution method for M.
Smegmatis, thesis’s tuberculosis-model bacteria.
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The broth microdilution method is based in the ability of the isolate (bacteria
suspension) to grow in broth containing a single antibiotic concentration. The
critical minimum concentration of an antimicrobial agent that prevents bacteria
growth represents the minimum inhibitory concentration (MIC) [76,77]. Briefly,
known quantity of bacteria is exposed to specified concentrations of one
antibiotic. Following overnight incubation, visible bacterial growth (as evidenced
by turbidity) is examined, and MIC is determined [78]. Using these standards,
the minimum bactericidal concentration (MBC), which is the lowest concentration
of the drug that kills ~99.9% of bacteria, can be determined.

1.4.

Approach: Ultrafine Particles as Drug Delivery System

Many treatment strategies to increase the dose of antibiotics inside alveolar
macrophages have been devised in recent years. Among them, drug
encapsulation in liposomes, nanoparticles (NP) or microparticles (MP) that can
undergo endocytosis by alveolar macrophages holds significant promise
[15,40,53,79,80]. Some advantages of using encapsulated drugs for infection
treatments are shortened treatment time, reduced dose frequency, and lower
doses [81]. In addition, by using drug-loaded particle systems the intracellular
delivery and bactericidal activity of antibiotics have shown significant
improvement when compared to that of the free drug [53,82–84].

Particles can be delivered by several administration routes, including inhalation.
One important benefit of the inhalation route for tuberculosis treatment is that the
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drug would be released to the desired site, directly to the alveolar macrophages
where M. tuberculosis is harboring. This would facilitate a faster antimicrobial
action, and help to reduce the long period of the current treatment. The main
advantage of the inhalation route resides in the fact that it eludes first-pass
metabolism, thereby reducing side effects, lowering drug dose, and more
efficiently targeting alveolar macrophages [6,85]. High intake of RIF could
present serious hepatic side effects, such as hepatotoxicity and renal failure [13].
Thus, in this work, the development of a particulate system able to efficiently
deliver the right drug amounts over time to alveolar macrophages is sought. The
RIF-loaded particulate system is envisioned as a pulmonary delivery of RIF.
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2.1. Materials
Rifampicin (RIF, >97% HPLC), D-(+)-Glucosamine hydrochloride (GluN-HCl, min.
99%), ethyl acetate (99.8%) and methanesulfonic acid (>99.5%) were from
Sigma-Aldrich, and ethanol (>99.5%) was received from McCormick Distilling
Co., Inc.. High molecular weight poly-L-lactide (HMW PLA, NatureWorks Ingeo™
8302D) with Mn = 123 kDa and polydispersity (PDI) 1.75 (GPC)) was purchased
from Jamplast, Inc. The L-lactide (LLA, 98%, Alfa) was re-crystallized from
toluene, vacuum-filtered in an argon atmosphere, vacuum-dried, and stored in a
desiccator. All the other chemicals and reagents were purchased from SigmaAldrich except where indicated. The low molecular weight poly-L-lactide and
GluN-LLA polymer synthesis is described in the next section.

2.1.1 Polymer Synthesis

Low molecular weight poly-L-lactide (LMW PLA, Mn = 2,500 Da, PDI=1.4 (GPC))
was synthesized according to a procedure published elsewhere [86]. The GluNLLA (Mn = 3,100 Da (NMR), PDI = 1.47 (GPC)) with average side-chain length of
11 monomeric L-lactide units, was prepared according to a procedure reported
earlier [1,2]. Briefly, 10 mL of methanesulfonic acid were transferred into a 50 mL
flask under argon atmosphere and placed in an oil bath kept at 40°C.
Subsequently, 3.5 mmol of GluN-HCl was added and stirred until
homogenization. Then, the L-lactide was added to the reaction mixture, and the
flask was flushed with argon for 10 minutes to remove the liberated gaseous HCl.
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Polymerization of L-lactide occurred for four hours, and the reacting mixture was
afterwards quenched with an acid-base neutralization solution, as described
elsewhere [2]. Vacuum filtration and vacuum drying overnight at the ambient
temperature were carried out to isolate and dry the product. Samples were stored
in a desiccator until use.

2.2. Particle Preparation and Characterization

2.2.1 Particle Preparation

Polymeric nanoparticles were prepared from a 5% (w/v) GluN-LLA or LMW PLA,
while microparticles were prepared from a 20% (w/v) GluN-LLA or 1% (w/v)
HMW PLA. The preparation of polymeric precursor solutions was done by
dissolving the corresponding polymers into ethyl acetate. These solutions were
processed into four different sets of particles using a conventional single-nozzle
EHDA setup. The resulting particles were labeled as SMP-GluN-LLA, SMP-LLA
and MP-GluN-LLA, MP-LLA, respectively. For the preparation of RIF-loaded
particles, three different drug loadings were used: 10, 20 and 50 wt%, which
correspond to RIF-to-polymer mass ratios of 1:10, 1:5 and 1:1, respectively,
being the 1:5 and 1:1 ratios the most studied in the present thesis. The precursor
solution was loaded into a Hamilton series 1000 gastight syringe (model 1001, 1
mL), then a 19 gauge, blunt needle was attached to the syringe (to serve as the
EHDA nozzle). Subsequently, the syringe was attached to a digital syringe pump
(Cole-Parmer 74900-00, Vernon Hills, IL). Voltage differences in the range of 5-
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15 kV, (Gamma High Voltage Research ES30P-5W/PRG, Ormond Beach, FL)
and a nozzle-to-collector distance of 10 cm were used in the course of a typical
experiment. Various flow rates in the range of 0.2-0.5 mL h-1 were tested to find
optimal processing conditions in order to make particles with narrow diameter
distributions. The particles were deposited onto an aluminum foil collector tightly
wrapped around 15 cm OD circular copper disk. The temperature and relative
humidity during the collection of particles were approximately 24ºC and 45%,
respectively. The collection time was limited to 10 minutes (optimization phase)
or extended up to a few days to collect amounts of particles suitable for further
studies.

2.2.2 Size and Morphology

Particle size and morphology were assessed via scanning electron microscopy
(SEM), using a Hitachi S-3000N microscope with an accelerating voltage of 15
kV and working distance of approximately 10 mm. Coating with metallic gold for 2
minutes before SEM characterization was used to enhance the contrast of nonconducting samples. The electrical current inside the chamber of the Technics
Hummer II sputter coater was kept constant (10 mA). Statistical analysis of
particle size measurements from SEM images was performed on sets of at least
250 counts within each specimen.
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2.2.3. Drug Release Studies

Drug release studies were performed under “perfect sink” conditions [26]. Briefly,
a mass equal to 50 mg of RIF-loaded particles was dispersed in 5 mL of
phosphate buffered saline (PBS) (n=3) (pH = 7.4) supplemented with 0.02% of
ascorbic acid as an antioxidant [40], the vials were kept in a thermostat/shaker at
37.0±0.1°C in the dark. Samples of 200 µl were extracted from each vial every
hour for the first 8 hours, and then every 24 hours. The total volume was kept
constant by replacing the extracted sample volume with 200 µl of fresh PBS. RIF
content was measured with a Beckman DU-640 spectrophotometer in the 250550 nm wavelength range. In the past, the RIF release kinetics had been
evaluated at the isosbestic point of the drug, and through its quinone degradation
product (330 nm) [38,71]. Absorbance values at 310 nm were used to calculate
the concentration of RIF in the absence of drug oxidation, which was prevented
by addition of ascorbic acid and a lack of sample exposure to light.

2.2.4 Particle Degradation

Polymer degradation studies were performed using a modified PBS (pH = 7.4)
solution: water was replaced with deuterated water to facilitate NMR analysis of
the released L-lactic acid. First, the pH of the PBS stock solution was adjusted to
7.4 with 1 M HCl, then water was evaporated and the remaining solid was dried
under vacuum. Then, the dry PBS powder was dissolved in deuterated water
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(D2O, 99.8 atom % D, Cambridge Isotope Laboratories) for further use. Solid
polymeric particles (50 mg) were dispersed in 5.0 mL of deuterated PBS and the
suspension was kept in the dark at 37 °C while shaking it. For NMR analysis, 0.5
mL aliquots were drawn every 24 hours and 1H NMR spectra were recorded on a
Bruker Avance 500 NMR spectrometer at 500.13 MHz to track the release of Llactic acid. Following analysis, samples were poured back into their respective
particle suspensions. These studies were done in triplicate for all tested particle
types, and for 14 consecutive days.

2.2.5 Drug Encapsulation Efficiency

Approximately 40-50 mg of RIF loaded particles were treated with 5 mL of
anhydrous ethanol for 10 minutes (L-lactide polymers are not soluble in this
solvent, RIF solubility in ethanol is roughly 10 mg/mL). The suspension was then
centrifuged, the supernatant transferred to a 30 mL beaker and subsequently
diluted to 15 mL. UV-Vis spectra of RIF in ethanol were recorded in the 250-550
nm range, and concentrations were calculated based on the absorption peak at
306 nm.

The drug content entrapped within the particles was analyzed with 1H NMR
spectroscopy, using deuterated chloroform (CDCl3, 99.8 atom % D, SigmaAldrich) as solvent. Characteristic signals of methyl groups of RIF (1.04, 0.89 and
0.62 ppm) and polymer matrices (1.60 ppm) were compared and used to
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calculate the drug-to-polymer ratio. Particles that were not treated with ethanol
were used as reference.

2.2.6. Thermal Properties of RIF Loaded Particles

Differential Scanning Calorimetry (DSC) runs were performed on Q100 machine
(TA Instruments, New Castle, USA), calibrated for temperature and heat flow
using indium (melting point 156.6 °C and ΔHm, 28.45 J/g, respectively). Two
analytical runs (to confirm repeatability) were performed on each sample at a
heating rate of 10°C/min., by ramping temperature from 0 to 300°C, and the
sample compartment was flushed with dry nitrogen flowing at 25 mL/min. An
empty hermetic aluminum pan was used as a reference.

2.3 Data Fitting and Statistical Analysis

Data fitting of temporal RIF release profiles was performed using non-linear
curve fitting built-in module of the Origin® 9.0 software. Typically, 60% of the data
points were used and fitted to the Korsmeyer-Peppas equation (as required by
the model) [26]. Statistical evaluation was performed using ANOVA test with pvalues below 0.05 and 0.01 considered as significant.
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2.4 Evaluation of Particle Effects on Bacteria

2.4.1 Bacterial Strain

M. smegmatis ATCC 607 was purchased from Hardy Diagnostics (Santa Maria,
CA), and cultured at 37ºC and 150 rpm in Difco Middlebrook 7H9 (BD
Diagnostics, Sparks, MD) medium supplemented with 0.5% (v/v) glycerol and
0.05% Tween 80 to prevent clumping, 10 µg/mL cycloheximide to prevent fungal
contamination, 50 µg/mL carbenicillin to prevent other bacterial contamination,
and ADS (0.5% bovine serum albumin, 0.01 M dextrose and 0.015 M NaCl). For
each experiment, a fresh overnight culture was prepared with a terminal OD600
reading less than 0.4.

2.4.2 Particle Toxicity on M. Smegmatis

Three million colony forming units (cfu) of freshly prepared mycobacteria were
inoculated in 10 mL of 7H9 complete medium for 1 hour at 37ºC before the
addition of different amounts of particles (0, 300, 600 and 1,200 µg/mL). The
cultures were maintained in the oven at 37ºC with continuous shaking at 150 rpm
for 24 hours, and then 10 µL of culture was inoculated onto 7H10 agar plates
(7H10 agar supplemented with the same ingredients as 7H9 complete medium
without Tween 80) without spreading out, and incubated at 37°C for 3 days to
produce visible colonies. Mycobacteria in 7H9 complete medium without particles
were considered the particle toxicity control. Pictures of agar plates were taken
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with a digital camera (24 Mega Pixels resolution); areas of the colonies formed
were quantified by ImageJ software.

2.4.3 Determination of Minimum Inhibitory Concentration (MIC)

The MIC of free RIF and RIF-loaded particles for M. smegmatis were determined
by standard macrobroth dilution techniques recommended by the Clinical and
Laboratory Standard Institute (CLSI). Briefly, a series of dilutions of RIF-free (0,
1, 2, 4, 8, 16, 32, 64, 128, 256, 512 µg/mL) and encapsulated RIF particles
(according to 1:5 RIF-to-polymer mass ratio, 0, 5, 10, 20, 40, 80, 160, 320, 640,
1280, 2560 µg of loaded particles/mL, and 1:1 ratio 0, 2, 4, 8, 16, 32, 64, 128,
256, 512, 1024 µg of loaded particles/mL) in 7H9 medium were prepared.
Bacterial suspensions were then added to each tube to make final inocula of 3 x
105 cfu/mL; the lowest concentrations in antibiotic formulations that inhibited the
visible bacterial growth after 24 hours were assigned as MIC using McFarland
turbidity standard value of 0.5 as reference. 10 µL of culture from each tube was
taken and then placed onto a 7H10 agar plate without spreading it out. The
plates were cultured at 37oC for 3 days before the colonies were analysed.
Minimum bactericidal concentration (MBC) was deﬁned as the smallest
concentration which kills at least 99.9% of bacterial population compared with
those in control vials.
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2.5 Evaluation of Particle Loading Effects on Macrophages

2.5.1 Cell Line

Mouse macrophage cell line J774A.1 was purchased from ATCC (Manassas,
VA). The cells were grown in Dubelco’s modified eagle’s medium (DMEM, Global
Cell Solutions, Charlottesville, VA) supplemented with 10% fetal bovine serum
(FBS, PAA Lab, Westborough, MA) and antibiotics containing 100 units/mL
penicillin, 100 µg/mL streptomycin and 250 ng/mL amphotericin B (Lonza,
Walkersville, MD) at 37oC and 5% CO2 in a humidified incubator.

2.5.2 Cytotoxicity of particles on macrophage cells

WST-8 assay (Dojindo Molecular Technologies, Inc) was performed per
manufacturer’s instructions. In brief, J774A.1 macrophages were seeded in 96well plates at a density of 1 x 104 cells/well, and incubated with SMP-GluN-LLA,
MP-GluN-LLA, SMP-LLA, and MP-LLA (0 (control), 30, 60, 120 and 240 µg/mL)
for 3 days at 37°C in humidified atmosphere (90% humidity), 5% CO2. WST-8
reagent solution (10 μL) was added to each well without changing medium, and
the plates were incubated for 1 hour prior to OD450 measurement with a BioTek
Elx800 microplate reader. Viability of J774A.1 cells was determined from the
absorbance of WST-8 in the cell suspension and sample without particle
exposure was taken as 100% viability.
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2.5.3 Particle Uptake, and Intracellular Localization by Confocal Microscopy

To determine the internalization of particles into macrophages, 4 x 10 5 cells were
seeded in 35mm glass bottom dishes (MatTek, Ashland, MA) and incubated for
48 hours with 120 µg/mL particles labelled with 1 % poly-caprolactonefluorescein conjugate (PCL-fluorescein, Advanced Polymer Inc, Carlstadt, NJ).
For these experiments, 1 % w/w PCL-fluorescein/polymer was added to the
GluN-LLA or PLA solution before particle fabrication. Subsequently, the cells
were stained with 100 nM of MitoTracker® or LysoTracker® (Invitrogen,
Carlsbad, CA) in serum-free and phenol red-free DMEM for 10 minutes.
CellMask™ plasma membrane staining (Invitrogen) was also performed to
confirm the particle internalization. Finally, cells were washed and visualized with
a confocal microscope (Olympus FV500-IX 81).

2.5.4 Intracellular Killing of M. Smegmatis

To examine the effects of RIF loaded particles on killing efficiency of M.
smegmatis in macrophages, 105 cells per well were seeded in 24-well plates and
allowed to grow for 24 hours before infection. After washing with antibiotics-free
medium twice, 20 multiplicity of infection (MOI: ratio of bacteria/cells) of fresh
growing M. smegmatis was used to infect the cells for 1 hour and then
extracellular bacteria were killed by the addition of gentamicin (20 µg/mL). Free
(30 µg/mL), or RIF loaded particles (60 µg/mL, according to 1:1 RIF-to-polymer
mass ratio), was then loaded into the cell culture with growing medium without
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antibiotics. After the incubation period, cells were washed and lysed with water
and intracellular survival was estimated by plating serially diluted cultures on
7H10 plates. Pictures of agar plates were taken with a digital camera (24 MP
resolution), and the colonies were counted after 3 days with ImageJ software. To
determine the relative population of surviving cells after infection, macrophages
were stained with the Live/Dead viability kit (Invitrogen, 4 µM EthD-1 and 2 µM
Calcein AM) before lysed. After 10 minutes of incubation with dyes, cells were
examined with VWR Vistavision Inverted Epifluorescence microscope attaching
to a LissView Imaging system. Live cells were counted with ImageJ software.
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3.1. Particle Fabrication: Optimization of Processing Conditions
The electrospray technique was used to prepare four sets of particles composed
of two different polymeric materials, GluN-LLA and PLA. These groups of
particles were labeled as SMP-GluN-LLA, MP-GluN-LLA, SMP-LLA, and MPLLA. In order to determine the optimal conditions for particle production,
electrospray variables such as polymer concentration, voltage, tip-to-collector
distance and flow rate were varied (section 1.3.1.3). Due to the fact that
ultimately, fully biocompatible drug delivery systems are desired, particles were
prepared using (the relatively less toxic) ethyl acetate solvent to dissolve GluNLLA and PLA polymers. An experimental setup similar to the one illustrated in
Figure 1.3 was employed to produce the particles. Particle size and morphology
was characterized by the processing of SEM images with Gimp 2.8 software. It
was determined that the simplest way to achieve particle size control was by
varying polymer concentration. Preliminary tests using the GluN-LLA oligomer
were performed at three different weight/volume percentages: 5, 10 and 15 (Fig.
3.1), while keeping flow rate in all cases at 0.5 mL/h. It is clear that at 5 kV,
average particle diameters increase (0.79, 0.91 and 2.62 µm) with increasing
polymer concentration, and that the particle size distributions (PSDs) were
relatively broad in all samples (standard deviation: 0.94, 1.01, and 1.88,
respectively). Increasing the processing voltage to 10 kV resulted in decreased
average particle diameters (Fig. 3.1B).
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The polymer concentration was then fixed at 5 %, and the flow rate was varied
from 0.2 to 0.5 mL/h, in 0.1 mL/h increments (Fig. 3.2). As it turned out, samples
processed at 5 kV displayed a bimodal PSD, with 80% of particles being in the
submicron region (Fig. 3.1, inset). This is normally indicative of either the
presence of more than one mode of electrified jet breakup, or the occurrence of a
“satellite” droplet formation mechanism [87]. At 10 kV, a practical PSD
unimodality was achieved at a flow rate of 0.3 mL/h, with only 3% of population
consisting of supramicron-sized particles. However, a tradeoff between
unimodality and particle diameter (if the general goal of using EHDA is indeed
making ultrafine particles) becomes apparent, as the former comes at the
expense of making larger particles (Fig. 3.2B).

Since in this dissertation, one objective was to focus on drug release from welldefined PSDs, it was preferred to process the samples at a flow rate 0.3 mL/h
and voltage of 10 kV. Interestingly, increasing the voltage to 15 kV did not lead to
smaller particle diameters. This effect is attributed to a multi-jetting mode being in
operation exclusively at 10 kV. The single-jet mode was observed at 5 and 15 kV.
The latter normally leads to larger particles relative to cases in which more than
one electrified liquid jet is ejected from the Taylor cone. This same trend was also
observed during the attempts to optimize the microparticle design from GluN-LLA
and HMW PLA, which suggests that this may be a characteristic of the solvent
system, rather than a solute effect.
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Figure 3.1. Control over particle size is achieved by varying the concentration of
GluN-LLA. Samples were solubilized in ethyl acetate and processed at 0.5 mL/h
flow rate and voltages of: A) 5 kV, B) 10 kV. With increasing voltage, the average
particle size decreases while particle diameter distribution becomes narrower.
Increasing polymer concentration increases the average particle size (◄). Box
range: 10-90%, whisker range: 5-95%, (x) 1-99%, (−) min. and max. values of
particle diameter within investigated population. Inset: bimodal particle size
distribution for sample prepared using 5 % w/v GluN-LLA concentration. Particle
diameter means are significantly different (p<0.01) at 5kV and 10kV.
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Figure 3.2. The effect of processing conditions, flow rate and voltage (A: 5 kV, B:
10 kV) on particle size and distribution. Particles were prepared using a 5% (w/v)
solution of GluN-LLA in ethyl acetate. Processing at 5 kV resulted in a bimodal
particle size distribution with 80% of the population in sub-micrometer range. Box
range: 10-90%, whisker range: 5-95%, (x) 1-99%, (−) min. and max. values of
particle diameter within investigated population Box plots present submicron
populations exclusively. Particle diameter means are significantly different
(p<0.01) at 5kV and 10kV.
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3.2. Fabrication of Pure, and RIF-loaded Submicron- and Micron-sized
Particles
The main objective of the in vitro drug release studies was to gain some insight
into the difference in behavior between the GluN-LLA and a broadly accepted
benchmark, LLA. Submicron particles based on LMW PLA (SMP-LLA) were
prepared from their 5% (w/v) solutions in ethyl acetate at the chosen processing
conditions (0.3 mL/h, 10 kV, 10 cm). In order to guarantee complete polymer
dissolution and avoid precipitation, the solution needed to remain at 40°C during
processing. The average particle diameter is somewhat smaller than those of
their branched counterparts (Table 3.1).

For the preparation of MP-LLA, a concentration of 1% (w/v) of HMW PLA was
found to be very close to the polymer’s solubility. Thus, this value was selected
for sample production under the same processing conditions. The MP-LLA in this
case were characterized by a toroidal shape (Fig. 3.3) which, based on gained
experience, is typically indicative of rapid solvent evaporation leading to imploded
“doughnut”- or “raisin”-shaped particles. On the other hand, virtually perfect
spherical MP-GluN-LLA are obtained with 20% (w/v) of GluN-LLA in ethyl acetate
when processed at a flow rate (Q) of 0.5 mL/h, voltage (V) of 10 kV, and
electrode-to-electrode distance (d) of 10 cm electrode-to-electrode distance (Fig.
1.3 and Fig. 3.3). For the preparation of SMP-GluN-LLA, a 5% (w/v) GluN-LLA in
ethyl acetate solution was used, which was processed under the same EHDA
conditions as their SMP-LLA counterpart (Q = 0.3 mL/h, V = 10 kV, do = 10 cm).
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The size and shape of the particles are crucial factors for delivery into the
pulmonary airways: particles with aerodynamic diameters between 1-5 µm are
preferred [49,88]. Particles with sizes larger than 5 µm are usually deposited in
the oral cavity, and particles smaller than <0.5 µm move by Brownian motion and
settle slowly. Nanoparticles (<100 nm) are not likely to deposit effectively in the
pulmonary airways because they are exhaled before deposition [49]. In this work,
two size ranges were intentionally made: SMP between 0.5 to 0.8 µm and MP
between 2 to 3 µm. In the past, equipment modifications to the EHDA system
were found to be necessary for particle micro-sizing i.e., to extract a fraction of
nearly monodisperse PLGA microparticles in situ, at the expense of a decreased
process efficiency [38]. In this dissertation, nearly monodisperse microparticles
were prepared without using any EHDA apparatus modification, and the particle
diameter ranges achieved fall within the targeted size ranges for the intended
drug delivery long-term application i.e., inhalation.
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Table 3.1. Polymers used in RIF release studies. Type, molecular weight (Mn),
processing solution concentrations and diameters (average ± SD) of pure and RIFloaded particles are presented. Voltage: 10 kV, and flow rate: 0.3 mL/h were used
unless specified otherwise

Polymer

Molecular
weight,
Da

Concentration,
%

Particle diameter, µm
c

GluN-LLA

3,100

LMW PLA
HMW PLA

2,500
123,000

5.0
b
20.0
5.0
1.0

Particle type
Pure polymer
SMP-GluN-LLA
0.50±0.30
MP-GluN-LLA
2.10±0.60
SMP-LLA
0.37±0.30
MP-LLA
2.90±0.90

a

1:5
0.57±0.45
–
0.87±0.80
–

a) RIF-to-polymer mass ratio used to prepare particles, i.e. 20% and 50% by weight,
respectively.
b) Flow rate 0.5 mL/h was used.
c) SMP: submicron particles, MP: microparticles

a

1:1
0.90±0.70
–
1.22±1.0
–
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Figure 3.3. MP-GluN-LLA (A) and MP-LLA (B) were prepared at discrete
voltages as indicated in respective plots. There are statistically significant
differences between all populations within the subsets A and B (p < 0.01). Insets
show the difference in particle morphology between low and high molecular
weight polymers prepared at 10 kV. Spherical MP-GluN-LLA resulted from
processing 20% (w/v) GluN-LLA (A). MP-LLA with toroidal shape were obtained
by using 1% (w/v) HMW PLA (B). Average particle size (◄), box range: 10-90%,
whisker range: 5-95%, (x) 1-99%, (−) min. and max. values of particle diameter
within investigated population.
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To evaluate the effect of drug loading on particle morphology (Fig. 3.4) and their
PSD (Fig. 3.5), tests were performed for SMP-GluN-LLA and SMP-LLA at two
drug loadings, namely 20 and 50 wt%, which correspond to RIF-to-polymer mass
ratios of 1:5 and 1:1, respectively (Fig. 3.4). It has been mentioned that very high
drug loadings and slow release profiles are two extremely desirable traits, and
this is exactly the reason why attention has been aimed on such high RIF
payloads.

At 20 wt% loading, the broadening of the PSD in this sample (5/1, SMP-LLA) and
that of the control differ in a statistically significant manner (*p<0.01), but this was
not observed in the SMP-GluN-LLA sample, as shown in Figure 3.5 panels A and
B. A loading of 50 wt% (5/5) resulted in further particle diameter increases, and in
broadening of the PSDs, which could be a consequence of the higher
concentration of polymer in the precursor solution. Differences in the particle
diameters of SMP-LLA and SMP-GluN-LLA were found to be statistically
significant at **p<0.01. An increased occurrence of general surface irregularities
have previously been observed (e.g., particles with wrinkled surfaces) in PLGA
microparticles with increasing RIF loading [38]. It is note however, that this is not
indicative of phase separation: in this work case, separate RIF crystals were
never observed by SEM.
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Figure 3.4. SEM images illustrating the gradually changing morphology of
polymeric submicronparticles made of low molecular weight polymers as RIF
content is increased: SMP- GluN-LLA (top row) and SMP-LLA (bottom row). Pure
polymeric particles (A, D) and with RIF-to-polymer mass ratios of 1:5 (B, E) and
1:1 (C, F) are presented. The scale bar (10 µm) is the same for all images,
except E (25 µm).

58

Figure 3.5. The effect of RIF loading expressed as polymer-to-RIF mass ratio,
average diameter and particle size distribution. Two low molecular weight
polymers were tested: A) SMP-GluN-LLA made with branched GluN-LLA, and B)
SMP-LLA made with linear LMW PLA. Particles were prepared at a flow rate of
0.3 mL/h and voltage of 10 kV. There are statistically significant differences
between SMP-GluN-LLA and SMP-LLA (5/5 polymer to RIF ratio) when
compared with their controls, subsets A and B (**p<0.01). At the 5/1 ratio, only
the SMP-LLA were statistically significant different when compared with its
control (*p<0.01). Average particle size (◄), box range: 10-90%, whisker range:
5-95%, (x) 1-99%, (−) min. and max. values of particle diameter within
investigated population.
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3.3. Drug Entrapment Efficiency
Time-release profiles from polymeric drug-loaded nano- and microparticles are
usually characterized by a set of basic stages: (1) initial burst release, (2) slow
diffusion-controlled release and sometimes, a (3) phase of abrupt release caused
by a final loss of structural integrity in the particles. Burst release occurs in the
first few hours, and it is commonly attributed to the fraction of drug located closer
to the particle surface. The objective in this experiment was to determine the
amount of drug that remains after this initial release had happened. While GluNLLA and PLA polymers are insoluble in ethanol, RIF solubility is 10 mg/mL. Thus,
in order to extract the drug from the outermost layers of the particle surface, RIFloaded particles were contacted with ethanol for 10 minutes. After ethanol
treatment, particles were fully dissolved and their remaining RIF content was
determined. The RIF loading efficiency measured by this ethanol leaching test
indicates that the GluN-LLA polymer is superior to its linear homopolymer
counterparts irrespective of molecular weight and characteristic dimensions of
the particles (Table 3.2). These results correspond to the amount of RIF retained
within the particles at the end of the initial 8-hour period when PBS was used.
The entrapment efficiency in the microparticles is comparable to those of RIFloaded PLGA microparticles prepared via the oil-in-water emulsification method
(57-78% for PLGAs with molecular weights of 10 and 20 kDa) [40]. They are also
well above those reported with RIF-loaded HMW PLA microparticles prepared via
the supercritical anti-solvent method performed at comparable drug-to-polymer
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ratios (40-50%) [55]. In general, the encapsulation efficiency calculated from
cumulative release curves well exceeded 90% for all tested LMW systems (Table
3.2), but is extremely low for HMW PLA. This is an expected result, as the low
degradation rates of this class of polymers often results in permanent drug
entrapment inside polymer network [63].
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Table 3.2. Encapsulation efficiency and kinetic parameters of RIF release from Llactide based polymeric submicron and microparticles (n = 3).

RIF:
Polymer

GluN-LLA
LMW PLA
GluN-LLA
HMW PLA

polyme
r ratio

Typed

RIF

Korsmeyer-Peppas

Encapsulation

release

equation fitting resultsc

efficiency, %a

efficiency,
%

b

n

k

R2

1: 5

SMP-GluN-LLA

56.0±0.1

97.5

0.13

0.29

0.90

1:10

SMP-GluN-LLA

-

96.6

0.15

0.28

0.90

1: 5

SMP-LLA

15.0±0.2

98.3

0.71

0.14

0.99

1: 5

MP-GluN-LLA

71.0±1.7

93.1

0.14

0.33

0.95

1:10

MP-GluN-LLA

-

98.1

0.22

0.25

0.93

1: 5

MP-LLA

52.0±0.9

7.0

0.10

0.54

0.98

a) The drug was extracted with pure ethanol for 10 minutes and the remaining solid
was analyzed via 1H NMR.
b) Results based on initial (6 and 12 µM for samples with 1:10 and 1:5 RIF-to-polymer
mass ratios, respectively) and cumulative drug loading.
c) Mt/M∞ = ktn, where k is the constant incorporating characteristics of the
macromolecular network system and the drug , n is the exponent describing release
mechanism, Mt/M∞ is the fraction of the drug released at time t.
d) SMP: submicron particles, MP: microparticles (see Table 3.1 for details).
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3.4. Rifampicin Release from Submicron- and Microparticles
The submicron- and micron-sized particles prepared with the GluN-LLA material
as carrier yielded the desired results i.e., they were efficient in releasing the drug
over a period of two weeks (Fig. 3.6). This efficiency was attributed to molecular
interactions between RIF and the polymeric matrix. Linear polymers appeared to
be less efficient than their branched counterparts in yielding strong molecular
interactions with the drug. SMP-LLA prepared using a LMW PLA with a similar
molecular weight to that of the glucosamine based oligomer allowed sustained
drug release for 30-40 hours, as shown in Figure 3.6. However, as much as 60%
of the drug was released within the first 8 hours. Similar results have been
reported for PLGA (Mw = 5-15 kDa) submicron-size particles loaded with
budesonide (MW= 430.5 Da) [89], and for RIF-loaded PLGA microparticles [40].
Increasing particle sizes from 165 nm to 289 nm extended the drug release time
from 25-30 hours to 60 hours. Notably, submicron-particles (diameters: 169, 289
and 400 nm) prepared by these authors using a core-shell electrospray (with a
coaxial, two-liquid nozzle) approach lost 60-40% of the initial drug payload in just
5 hours. This was found to take place despite the protection provided by a shell
made of PLGA (100% drug encapsulation). The fact that these authors used the
same drug release protocols as used in this dissertation is of utmost importance
when comparing results from different sources. For example, it has been
demonstrated that stirring speed significantly affects the dissolution rate profiles
of RIF-loaded PDLLA microparticles [71].
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Figure 3.6. Cumulative RIF release curves from submicron and microparticles.
Release curves correspond to SMP-GluN-LLA (▲), MP-GluN-LLA (♦) with RIF-topolymer mass ratios of 1:10 and SMP-GluN-LLA (Δ), MP-GluN-LLA (◊), SMP-LLA
and MP-LLA (star symbols) with RIF-to-polymer mass ratios of 1:5. Insets show
the release profiles during the first 8 hours. Data represent means ± SE (n=3).
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There is little difference between the drug release kinetics from nano- and
microparticles made of GluN-LLA at 10 wt% and 20 wt% payloads (curves SMPGluN-LLA (1:10) and MP-GluN-LLA(1:5) in Fig. 3.6, respectively). The ability of
the new polymers to stabilize high drug payloads is also a most desirable trait,
and it suggests the occurrence of a similar release mechanism for both particle
diameter groups. This is consistent with particle size-encapsulation efficiency
relationships reported by others [89].

For all samples, two stages of RIF release can be identified; an initial one, up to
8 hours (Scheme 3.1, Step 1 and Fig. 3.6, insets), and a delayed phase, from 8
to more than 300 hours (Scheme 3.1, Step 2 and Fig. 3.6). It is also apparent
that the RIF release from SMP-LLA was mechanistically different than that from
the GluN-LLA materials. This could be attributed to their different molecular
architectures and functionalities, since both polymers have very similar molecular
weights (Table 3.1). For LMW PLA, the drug release followed an anomalous,
non-Fickian diffusion model (n = 0.71, Table 3.2) as defined by Ritger and
Peppas (0.43 < n <0.85) [26,29]. The Korsmeyer-Peppas equation (see
annotation c in Table 3.2 for details) predicts a diffusion-controlled drug release
mechanism for systems with diffusion exponent ‘n = 0.43’. All tested GluN-LLA
submicron- and microparticulate systems have much lower n-values (0.13-0.22,
Table 3.2). This is indicative of drug-polymer matrix interactions [27], and these
results are also consistent with encapsulation efficiency tests and DSC results
(discussed next section).
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Scheme 3.1. Representation of the bimodal kinetics of RIF release from the
GluN-LLA carrier: 1) initial, 2) delayed. In the delayed phase the drug passes
through pores created by molecules released in the initial phase (k1 > k2). In
both phases the effects of drug-polymer interactions were evident and seen as
decreased values for the n exponent in the Korsmeyer-Peppas equation (Table
3.2).
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3.5. Particle Degradation and Thermal Properties: Impact on Drug Release
Kinetics

The degradation studies performed under identical conditions as those from drug
release measurements revealed that L-lactic acid (LLA) release is proportional to
the available contact surface between polymeric particles and the solution (Fig.
3.7). All tested polymers are hydroxyl-terminated and on a molecular level, the
degradation mechanism for these polymers is end chain scission [90]. Both types
of nanoparticles exhibited similar degradation curves, but after two weeks the
LLA concentration was higher for SMP-GluN-LLA, 8.2 x 10-3 mM, than the 4.0 x
10-3 mM observed with SMP-LLA. Overall, material loss due to degradation
accounts for only 5% of the initial mass in 14 days of experiment, and thus has
negligible effect on the RIF release mechanism.

The DSC measurements revealed that the RIF used in this dissertation is the
stable type I form (a single, sharp exothermic signal, peaking at 253°C is the only
feature in its thermograms) [91]. The glass transition temperatures (Tg) for RIFloaded submicron- and microparticles prepared with GluN-LLA increased by 810°C when compared to that of the pure polymer (Fig. 3.8 thermograms b, c and
d) [1]. This is indicative of enhanced drug-polymer molecular interactions, i.e. RIF
likely binds to terminal hydroxyl groups of GluN-LLA chains, thereby increasing
its “effective molecular weight”, as evidenced by augmented T g values. On the
other hand, introduction of RIF is less likely to be responsible for the observed
differences in thermal properties between pure and drug-loaded LMW PLA
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nanoparticles. The as-prepared material is highly crystalline and there is no
distinguishable characteristic glass transition inflection point seen in its
thermogram (Fig. 3.8 f). However, rapid solvent evaporation during processing
results in semi-crystalline features: Tg (46 °C) and an exothermic “cold
crystallization” peak at 77°C were followed by an endothermic melting peak at
133°C. If the drug occupied exclusively the limited available amorphous polymer
regions and molecular interactions were thus very weak or absent, then it would
be rapidly released upon contact with the PBS solution (Fig. 3.7) or ethanol
(Table 3.2).

Differences in molecular architecture have a pronounced effect on the thermal
properties of these polymers: while GluN-LLA is purely amorphous, as evidenced
by the previously reported DSC results, Tg = 43.7±1.3°C and the absence of the
melting peak of the crystalline phase [1], the LWM PLA has semi-crystalline
characteristics (Fig. 3.8 f) [92]. The DSC results suggest that chain length is a
decisive crystallinity control factor for oligo-L-lactides, and transition from an
amorphous to a semi-crystalline form takes place for monomer numbers higher
than 10-12. In view of the results presented in this thesis, the advantages of
using branched over linear molecular architectures for RIF delivery applications
are apparent. The fine-tuning of the polymeric matrix crystallinity (a strategy that
is sometimes used as an important drug release control factor) requires detailed
knowledge of its thermal properties, and often demands the use of an additional
post-processing step [93]. In matrices with reduced crystallinity, drug-polymer
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interactions are enhanced. This in turn, leads to efficient dispersion of the drug
within the polymer matrix, making these systems favorable for applications
requiring slow release of the drug [94]. The current polymeric materials have
potential for designing ultrafine particle based tuberculosis treatment systems: a
typical tuberculosis treatment lasts about 6 months [4,7].
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Figure 3.7. Semi-log plot of degradation of submicron- (open symbols) and
micron-sized particles (filled symbols) prepared using linear (left panel) and
branched (right panel) L-lactide based polymers. The release of L-lactic acid was
tracked via 1H NMR spectroscopy. Data represent means ± SE (n = 3).
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Figure 3.8. DSC thermograms. a) RIF, b) as prepared GluN-LLA polymer, c) RIF
loaded SMP-GluN-LLA, d) RIF loaded MP-GluN-LLA, e) RIF loaded SMP-LLA f)
as prepared LMWPLA. For samples c-e the RIF-to-polymer ratio was 1:5.
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3.6. Particle Toxicity on M. Smegmatis
Chitosan, the polymeric form of glucosamine, has been regarded as a
biomaterial with bactericidal properties [95,96]. Melake et al. [97] reported on its
cytotoxic effect on P. aeruginosa, with LMW chitosan showing a higher
bactericidal activity compared to its medium and high molecular weight forms.
Also, Liu et al. found higher cytotoxic effects with high molecular weight chitosan.
The most accepted mechanism of its antibacterial action is believed to involve
the positive charge of the protonated amine groups [98].
Figure 3.9 shows the changes in % of growth area compared to control for SMPGluN-LLA, MP-GluN-LLA, SMP-LLA and MP-LLA at 300, 600 and 1,200 µg of
particles/mL. It was hypothesized a priori that the presence of a glucosamine
core in GluN-LLA was going to possibly contribute some antibacterial activity on
M. smegmatis, but as shown in Fig. 3.9, this was not the case. Changes in
bactericidal activity for all particle types and for all concentrations were not
statistically different when compared to the control.
However, significant statistical differences exist among particle materials (MPGluN-LLA vs MP-LLA, # p<0.01). While GluN-LLA particles do not affect bacteria
survival, MP-LLA seems to favor M. smegmatis growth. This can be explained by
the high correlation between microbial adhesion and the hydrophobic/hydrophilic
characteristics of the interacting surfaces. In this regard, it has been shown that
the adhesion of bacteria to solid surfaces is positively affected by the surface’s
hydrophobicity [99,100]. Oliveira et al. performed adhesion experiments between
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different bacteria and polymeric surfaces. These authors found surface
hydrophobicity to be proportional to the number of adhering bacteria [101]. Thus,
it is hypothesized that MP-LLA promotes bacterial growth compared to MP-GluNLLA, and that bacterial adhesion to MP-LLA particles possibly facilitated bacterial
proliferation.
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Figure 3.9. Particle toxicity on M. smegmatis. Mycobacteria were inoculated with
different amounts of submicron- and micron-sized particles and were cultured for
24 hours. 10μL of culture was placed onto agar plates and incubated at 37ºC for
three days to see visible colonies. Colony area was quantified from agar plates
pictures by ImageJ software. Statistically significant differences between SMPGluN-LLA and MP-LLA (+p<0.05); and between MP-GluN-LLA and MP-LLA
(*p<0.05) at a particle concentration of 600 µg/mL, are shown. Statistically
significant differences are shown between MP-LLA and MP-GluN-LLA, which is
indicative of promoted bacterial growth by the linear LLA when compared to the
branched GluN-LLA material (# p<0.01). Data represent means ± SE (n=3).
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3.7. Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal
Concentration (MBC) of Free RIF and RIF Loaded Particles
Table 3.3 summarizes the MIC and MBC results for free and encapsulated RIF
and shows pictures of bacteria after 3 days of incubation in a 7H10 agar plate.
These images were used to determine the MBC values. For particles loaded at a
1:1 RIF-to-polymer mass ratio, SMP-GluN-LLA and MP-GluN-LLA showed MIC
values that were about half of that of free RIF on a same dose of antibiotic basis.
SMP-LLA showed MIC value 4 times lower than MIC value of RIF alone, while
MP-LLA showed MIC value similar to that of RIF alone. MBC values were also
affected by encapsulation: SMP-GluN-LLA and SMP-LLA showed MBC values 2
times lower than free RIF, while MBC values for MP-LLA and MP-GluN-LLA were
unaffected.

Improved efficacy of antibiotics encapsulated in polymer particles and liposomes
and intracellular delivery of antibiotics on different microbial strains has been
reported. Mirzaee et al. [82] have found decreased values of MIC for
encapsulated amikacin compared to free amikacin for E. coli, P. aeruginosa, S.
faecalis and S. aureus. In the same manner, liposomes as encapsulants for
amikacin, gentamicin and tobramycin reduced the MICs for highly antibioticsresistant strains while improving the uptake of antibiotics into the bacterial cells
[83]. Meropenem and tobramycin encapsulated in liposomes inhibited the growth
of bacteria using sub-MIC concentrations of antibiotic [84,102]. In both cases, the
bactericidal activity of the antibiotics was increased when compared with that of
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the free drug. One possible explanation for this phenomenon is membrane fusion
between liposomes and bacteria, which would deliver a high dose of antibiotic to
the microorganism and therefore surpassing the bacteria efflux pump capacity
[103,104]. Another example where the bactericidal effect was also enhanced was
shown by the use of RIF-loaded particles. PLGA microparticles loaded with RIF
showed a greater bactericidal effect on Mycobacterium bovis Bacillus CalmetteGuérin (BCG) in alveolar macrophages cells than that of RIF in solution at the
same periods of time [53]. Similar results were obtained by Makino and
coworkers [40], but in this case higher amounts of RIF were detected inside
alveolar macrophages cells treated with RIF-loaded microparticles than when
treated with RIF alone.
Antimicrobial activity of the drug-free GluN-LLA and PLA particles was evident in
figure 3.9, where it is shown that the RIF-free GluN-LLA particles present no
antibacterial properties on M. smegmatis. However, MIC reduction in RIF-loaded
GluN-LLA and SMP-LLA particles indicates an increase in bacterial killing relative
to free RIF. The mechanism by which RIF encapsulation on GluN-LLA particles
act this way has not yet been investigated. The physicochemical characteristics
of the GluN-LLA polymer are reflected by the differences in the observed MIC
values. At this stage, it is possible to speculate that surface charges of the
polymer attract bacteria to the particle surface exposing them to a locally high
antibiotic concentration.
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Table 3.3 MIC and MBC values (μg/mL) of RIF in both free, and encapsulated forms
were determined by the macrobroth dilution technique. Particles were produced with a
1:1 RIF-to-polymer mass ratio. Images from agar plate of M. smegmatis incubated for 3
days after contact with RIF-loaded particles and free RIF
RIF concentrations (µg/ml)
MIC MBC
Free RIF

64

256

32

128

32

256

SMP-LLA 16

128

1

2

4

8

16

32

64

128

256

512

2

4

8

16

32

64

128

256

512

1024

SMPGluN-LLA
MP-GluNLLA

MP-LLA

64

256

Amount particles
(µg/ml)
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3.8. Cytotoxicity of Particles on Macrophage Cells
In order to determine the cytotoxicity of the four sets of particles, the WST-8
viability assay was implemented. Figure 3.10 shows the survival rate (%) of
macrophages after three days of incubation with the drug-free (no RIF) particles.
Cytotoxicity was shown to be dose dependent i.e., at increasing particle doses
there was an increase in cell death. Cytotoxicity was not significantly affected by
the material type; at one specific dose level, all particle types showed a very
similar effect. When comparing particle concentrations with the control, all particle
types showed statistically significant differences at 120 and 240 µg/ml. At a
concentration of 60 µg/ml, only SMP-GluN-LLA particles showed significantly
different cytotoxicity levels in macrophages relative to its controls. The clear
inhibition in macrophages proliferation that occurs at a particle concentration of
120 µg/ml and at higher values can be due to an accumulation of free lactic acid
in the culture media. As a product of polymer degradation, lactic acid could cause
a localized lethal decrease in pH. This has been previously proposed to explain
the cytotoxic effect observed with LLA grafted chitosan [2]. The cytotoxicity result
(~20%) of SMP-GluN-LLA particles could be also correlated with its high cellular
uptake (shown in Fig. 3.11), and smaller particle size. The increasing number of
particles undergoing endocytosis could cause an increment in the production of
reactive oxygen species (ROS), which can lead to toxicological effects. In
addition, ROS generation is strongly favored by a decrease in particle size, which
necessarily translates into an increase in specific surface area [105].
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Figure 3.10. Particle cytotoxicity on J774A.1 Macrophages. Different
concentrations of GluN-LLA and LLA submicron and microparticles were
incubated with macrophages for 3 days. The WST-8 reagent solution was
contacted with the samples for one hour prior to OD450 measurement with a
BioTek Elx800 microplate reader. Cytotoxicity of submicron and microparticles
increased with increasing particle doses. All particle types’ cytotoxicity effects
were statistically significant in terms of particle concentration when compared to
their controls (*p<0.05). Data represent means ± SE (n=4).
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3.9. Intracellular Localization of Particles by Confocal Microscopy
Particle properties such as hydrophobicity, size, shape, and surface charge affect
cellular uptake [106]. When particles are introduced in the growth media they
adsorb various proteins. Hydrophobic surfaces produce denaturation of adsorbed
proteins, which could negatively affect the particle uptake by cells [105]. After
internalization, particles can follow two major pathways leading to programmed
cell death (apoptosis), namely the death receptor, or the mitochondrial pathway
[107]. The polyvalent surface of nanoparticles may induce cross-linking of cellular
receptors, trigger signaling processes, induce structural alterations at the cell
surface, and eventually interfere with normal cell function [108,109].
Particle internalization and uptake into cells could lead to mitochondria swelling
and an increase of mitochondrial membrane permeability which eventually
causes mitochondrial dysfunction, ROS production, and initiation of an apoptotic
signaling cascade [106]. In addition, upon internalization, particles could target
lysosomes, leading to lysosomal membrane damage and dysfunction. It was
reported that particle induced cell death is related to lysosomes localization in
cancer cells [110]. Macrophages tend to engulf particles between 0.5-5 µm rather
than nanoparticles. In addition, charged particles generally lead to better uptakes
than uncharged particles [111]. In this study, GluN-LLA particles displayed higher
uptake than PLA particles, as shown in Fig. 3.11.
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Figure 3.11. Internalization of particle by macrophages. Submicron- and micronsized particles made out of GluN-LLA and LLA labeled with PCL-fluorescein were
incubated with macrophages. Cells were washed and analyzed with confocal
microscopy. The fluorescence intensity/cell of the different types of particles was
quantified by ImageJ software. Macrophages showed statistically significant
higher submicron- and microparticles uptake made with the branched GluN-LLA
polymer than the particles made with the linear LLA polymer. Statistically
significant differences (**p<0.01), and statistically significant differences when
comparing with all populations (++p<0.01) are seen. Data represents means ±
SE (n=4).
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Previous studies showed that PLGA microparticles loaded with RIF colocalize in
phago-lysosomes [112], suggesting that released RIF molecules diffuse first
through the membrane of the phagosomes containing particles to the cytoplasm
and then, also by diffusion, enter the phagosomes containing the bacteria. The
particles studied in this thesis were internalized but surprisingly, did not
colocalize in mitochondria or lysosomes. After phagocytosis, they remained in
the cytoplasm (Fig. 3.12 parts A and B). What was found to be of critical
relevance to the proposed medical application is that the absence of
mitochondrial colocalization of particles is extremely desirable: if macrophage
targeting is intended, particle colocalization in this organelle is expected to
promote oxidative stresses that could lead to cell death. In these studies, particle
cytotoxicity on macrophages was directly related to particle dose (Fig. 3.10).
However, according to the results particle colocalization cannot be the culprit of
these cytotoxic effects, as shown in Fig. 3.12 (A and B). A sustained release of
RIF directly into the cytoplasm produces a strong concentration gradient within
phago-lysosomes containing the bacteria. Therefore, RIF diffusion through the
bacterial membrane and intracellular killing is highly improved. What is also of
key relevance to the goals of this study is that GluN-LLA particles showed higher
uptakes by macrophages compared to those made from LLA. This property can
obviously be very desirable when considering the design of a macrophagetargeting drug delivery system [79,113]. Thus, these polymers meet two
important requirements for anti-tuberculosis drug delivery applications, namely a)
high macrophage uptakes and b) low cytotoxicity.
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Figure 3.12. Intracellular localization of particles. Mitochondria and Lysosome
were stained with mitotracker and lysotracker, respectively. In order to be
visualized particles containing PCL fluorescein were produced. Part A shows the
images of lysosome stained cells: cytoplasm membrane staining (blue) and
lysosome staining (red) after incubation with fluorescein loaded particles (green).
Part B shows the images of mitochondria stained cells: mitochondria staining
(red) after incubation with fluorescein loaded particles (green). Particles are
engulfed by the cells but they do not colocalize either with mitochondria or with
lysosomes i.e., they stay in the cytoplasm. The scale bar is 20 µm for all images.
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3.10. Intracellular Killing of M. Smegmatis

In order to evaluate the in vitro mycobactericidal effect of RIF-loaded GluN-LLA
and PLA particles on M. smegmatis inside phagosomes, macrophages were first
exposed to a high multiplicity of infection (MOI of 20 bacteria per cell) to facilitate
infection, and after washing away the extracellular microorganism fraction,
infected cells were contacted with RIF loaded particles (1:1 RIF-to-polymer mass
ratio). For control and comparison purposes, free RIF and no-treatment samples
were included in this experiment. To determine the intracellular killing
effectiveness of free and encapsulated RIF, the ratio between the number of
intracellular bacteria (c.f.u.) and the number of cells alive at the same time point
was examined.
The no-treatment control experiment, which can be seen as the inset of figure
3.10, shows the cyclical behavior of killing/growth of M. smegmatis inside
J774A.1 macrophages. This pattern has been observed by others [114,115]. The
dynamic cycle of killing/growth phases is based on M. smegmatis’ ability to grow
fast, and to significantly delay phagosome maturation for a few hours. After an
exponential growth stage inside the macrophages, the mycobacterium is partially
or totally killed by the macrophages, depending on the extent of infection [114].
Anes et al. observed this cyclic interplay between killing and surviving of M.
smegmatis in J774 macrophages cultures with MOI values of 5-10, and within 48
hours macrophages were able to kill M. smegmatis. In order to test the killing
efficiency of a sustained release of RIF (from GluN-LLA particles) for a long
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period of time (10 days), a very high MOI of 20 was used in this dissertation.
Note that in the case of a pathogenic mycobacterium like M. tuberculosis, such
high level of infection would naturally cause macrophage apoptosis, which in this
context represents an innate defense against intracellular infection. Lee et al.
studied macrophage apoptosis as a function of level of bacterial infection, and
determined that M. tuberculosis rapidly induces cell apoptosis (90% in 20hrs) for
MOI>10. Also, these authors’ study showed that M. smegmatis caused a minimal
effect in macrophage death at MOI 25 and 50 [116].
Since the objective of this experiment was to evaluate the performance of RIFloaded particulate systems, and to compare with free RIF for 10 days, the
amount of free or encapsulated RIF added was half of the MIC measured (see
table 3.3). Considering these experimental conditions, and the induced high
infection levels, total killing of bacteria was not expected. One of this thesis’ goals
was to determine the effect of prolonged drug release compared to free RIF. At
half MIC, free RIF was very effective in killing intracellular bacteria during the first
5 days, as shown by the linear dependence found between c.f.u/cell with time
(Fig. 3.13). After day 5, a cyclic pattern was apparent, indicating a reduction in
RIF effectiveness. In the case of encapsulated RIF, all systems showed an
oscillatory behavior, with a significant reduction in c.f.u/cell values when
compared to the control. Also, contrary to free RIF, particulate systems showed
to be more efficient in killing bacteria after day 5. This result could be explained
by the loss of bioavailability of free RIF in culture media at 37°C, where 50% is
degraded after one week [117], while the encapsulated drug may be protected
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against such degradation processes. The number of intracellular bacteria per cell
in GluN-LLA and PLA polymers seems to be related to the RIF release
mechanism. Both GluN-LLA and SMP-LLA systems presented higher number of
intracellular bacteria per cell than free RIF during the first 4 days, but superior
killing efficiencies after day 6. On the other hand, the MP-PLA polymer showed a
different behavior: Like with free RIF, the oscillations in this case were strongly
attenuated for the first 6 days, which is probably caused by the high burst release
of the drug in this system (Figure 3.6, ~50% in 1 hr and ~70% in 8hrs). From
these observations, it is clear that one can use these polymers to devise a drug
release system, possibly a dual particle system, whose drug release profile can
be engineered virtually at will.
It is worthy of mention that after a thorough literature search, studies to assess
the effect of RIF-loaded particles on M. smegmatis inside macrophages for more
than one day were not found. To the best of the author’s knowledge, this
dissertation presents, for the first time, an experiment to evaluate the
performance of ultrafine particles on M. smegmatis inside macrophages as a
tuberculosis model for 10 days, and with a daily sampling frequency. The reason
for the scarcity of studies dealing with this particular problem is probably due to
the fact that macrophages kill M. smegmatis in 48 hrs for MOI values ≤ 10. For
example, Sonawane et al. [118–120] have done several antibacterial assessment
of starch- and chitosan-coated silver nanoparticles on infected mouse
macrophages (M.smegmatis, MOI=10). In their work, sampling of intracellular
bacteria survival was usually performed between 6 to 8 hours after infection.
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Figure 3.13. Intracellular killing of M. smegmatis. Macrophages were infected
with M. smegmatis at an MOI of 1:20 (cells:bacteria). After infection
macrophages were contacted with free RIF, and or RIF loaded particles. Inset
shows control experiments where M. smegmatis showed a cyclic growth/killing
pattern of colony forming units of intracellular M. smegmatis per macrophage cell
in terms of time.
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CHAPTER 4
Conclusion and Proposed Future Research

89
4.1. Conclusions
Using a new biocompatible polymer system based on glucosamine and L-lactide,
submicron- and micron-sized particles loaded with RIF via an
electrohydrodynamic atomization route were prepared. As comparator, low- and
high-molecular weight poly-lactic acid materials were used. Control over particle
size in a broad range was achieved by adjusting polymer concentration.

A sustained RIF release from submicron- and micro-sized particles for 14 days in
vitro was observed. These temporal profiles are composed of two clearly
discernible stages: an initial drug release phase (up to 8 hours) from the
outermost layers of the particles, followed by a delayed release phase. A nearly
linear RIF release profile was observed for several days in the delayed phase for
GluN-LLA submicron- and microparticles, and for the drug loadings of 10 and
20%, respectively. After 14 days, degradation of the polymer matrix accounts for
a loss of only 5% of the initial particulate mass, and its effect on the drug release
mechanism is likely negligible. The Korsmeyer-Peppas equation represented the
observed drug release behavior very well, which indicated that a modified
diffusion-controlled release kinetics mechanism of RIF took place in all tested
GluN-LLA systems. Low diffusion exponent values are indicative of enhanced
drug-polymer matrix interactions. This is consistent with DSC results, i.e. a shift
of 8-10°C towards higher temperatures in the observed glass transition
temperature for drug loaded GluN-LLA particles. Drug encapsulation efficiency
evaluated via ethanol leaching is also in line with the DSC findings. Four terminal
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hydroxyl and one primary amine groups are present in GluN-LLA molecules, as
opposed to just a single terminal hydroxyl moiety in the linear LMW PLA.
Increased hydroxyl density could facilitate the enhancement of polymer-RIF
interactions (five hydroxyl groups in the drug molecule) via hydrogen bonding.
Thus, molecular affinity seemed to have been the dominant release mechanism
in this case.

Polymers that show high macrophage internalization without colocalization into
different organelles are excellent candidates for the production of antituberculosis drug carrier particles. This was the case with glucosamine/L-lactide
based polymers: the drug-loaded particles remain in the cytoplasm, releasing RIF
in close proximity to intracellular bacteria. Intracellular killing of M. smegmatis by
different particles showed a cyclic interplay between live and dead bacteria. The
presence of free or encapsulated RIF at sub-MIC concentrations was effective in
reducing the number of bacteria per cell compared to the control. It is suggested
that the combination of different particle types and sizes involving at least one
type of particle made from the new polymers used in this study will ultimately
lead to the design of a system with optimal drug release profiles.

This thesis’ overarching goal was to design a drug delivery system capable of
attacking the microorganism over a long period of time and with just one dose.
For a given set of chemical characteristics that could lead to carrier-drug
interactions, polymeric materials with higher branching point densities and with
amorphous structures may in principle extend RIF release times. The
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development of such materials is an important area of research in the field of
design of drug delivery systems for the treatment of tuberculosis. The in vitro
results presented in this dissertation indicate that glucosamine/L-lactide
polymeric systems are promising candidates for this particular application.

4.2 - Proposed Future Work

This dissertation has presented an approach for the development of a sustained
drug delivery system as a potentially viable model for the treatment of
tuberculosis. The proposed system is composed of biodegradable rifampicin
(RIF)-loaded ultrafine particles. However, there would be certain areas to explore
before the proposed drug delivery system can be developed into an effective
nasal delivery vehicle for tuberculosis. This section will describe possible future
directions in the evaluation of GluN-LLA ultrafine particles for RIF lung delivery.

(1) In vitro evaluation of a Dual-Particle System. Section 3.10 in Chapter 3
discusses the in vitro intracellular killing of the model bacteria from free and
encapsulated RIF, and the superior performance of the particle system was
demonstrated. In addition, and especially after Figure 3.13 is reexamined, one
future experiment can be envisioned, namely the in vitro evaluation of a dual
particle system for the RIF lung delivery as a treatment for tuberculosis.
Specifically, a system containing MP-GluN-LLA and SMP-LLA would potentially
combine the individual qualities of each particulate system. MP-LLA burst release
would provide high extracellular RIF concentrations during the first eight hours of
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the treatment (figure 3.6), and keep releasing the remaining drug in it over the
course of 3-4 days. On the other hand, SMP-GluN-LLA (which undergoes
endocytosis) would provide an intracellular sustained release of the drug for
more than 12 days. Since drug release profiles of dual-particle systems can in
principle be engineered at will, superior bacterial killing by such approach can be
envisioned. In vitro drug release studies and intracellular killing evaluation using
the procedures explained in sections 2.2.3 and 2.5.4 could then be proposed for
the dual-particle systems listed in table 4.1. If one or two such systems showed
improved behavior in vitro over the already tested single particle system, they
would offer the possibility for advancing to an optimization stage, and ultimately
toward in vivo research phase.

Table 4.1. Dual particle systems (PDS) proposed for
future experimentation
PDS

Particle combinations in a 1:1 ratio (initially)

PDS-1

SMP-GluN-LLA and SMP-LLA

PDS-2

MP-GluN-LLA and SMP-LLA

PDS-3

MP-GluN-LLA and MP-LLA

PDS-4

SMP-GluN-LLA and MP-LLA
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For work beyond this dissertation, in vivo experimentation would be the next
logical step to evaluate GluN-LLA nano- and microparticles for their intended
purpose. To put things in perspective, in vivo studies have only demonstrated
thus far sustained release of RIF from PLGA nanoparticles for up to 4 days (but
via single oral administration [121]), so the need for improving these particle
formulations for delayed release of RIF remains strong, and the need for
investigating other forms of drug delivery (e.g., intranasal) remains unaddressed.

The development of new polymeric material variants within this drug carrier
family, for example with a higher degree of branching and amorphous structures
that enhance RIF-matrix interactions, could in principle lead to additional
improvements. In summary, the in vitro performance of GluN-LLA particles
showed the essential features of high drug loading, slow sustained release,
endocytosis by macrophages, MIC reduction, and intracellular killing of bacteria.
These characteristics would warrant in vivo experimentation, even if these
systems were by sheer luck, close to the optimum formulation. Such experiments
are proposed below.

(2) Intracellular killing assessment of M. tuberculosis in a mouse model.
Animal handling and experimentation should be conducted following IACUC
approval, standard protocols and approved guidelines. A mouse model is
convenient and economical, yet with an animal size large enough to allow for
drug administration, blood sampling and various tissue analyses and
pharmokinetics [122–125]. For this study, Swiss mice would be infected with M.
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tuberculosis H37Rv bacilli through the conventional aerosol route (Glascol
inhalation route) [122–124], and randomly divided into an ideal set of groups as
described in table 4.2. For statistic validation, each group would be composed of
at least four animals, but ideally six. For comparison purposes, mice in control
group 1 would not be treated with RIF, and groups 2-to-4 would receive “bank”
particles (no drug) via the inhalation route. Animals in groups 5 to 13 would be
treated weekly by inhalation of RIF-loaded particles at three doses levels (see
Table 4.2). Group 14 would be composed by mice receiving free RIF orally seven
days at a week. As it was mentioned before, a combination of GluN-LLA and PLA
particles for the lung delivery of RIF is a priori promising, and for this reason,
groups 4, 10 and 13 are optional, depending on their performance in in vitro
experiments. Twenty one days after infection [123], each group would be treated
as indicated in table 4.2.
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Table 4.2. Proposed Swiss mice groups for in vivo experimentation for oral and
inhalation treatments.
Group

Treatment would start 21 days post infection

1

Untreated control

2

SMP-GluN-LLA (weekly dose)

3

MP-GluN-LLA (weekly dose)

4*

PDS-X (weekly dose)

5

RIF loaded SMP-GluN-LLA (weekly dose 1)

6

RIF loaded MP-GluN-LLA (weekly dose 1)

7*

RIF loaded PDS-X (weekly dose 1)

8

RIF loaded SMP-GluN-LLA (weekly dose 2)

9

RIF loaded MP-GluN-LLA (weekly dose 2)

10*

RIF loaded PDS-X (weekly dose 2)

11

RIF loaded SMP-GluN-LLA (weekly dose 3)

12

RIF loaded MP-GluN-LLA (weekly dose 3)

13*

RIF loaded PDS-X (weekly dose 3)

14

RIF (daily dose O)

Treatment and
dosage
No treatment
Inhalation Treatment
with drug-free
particles
No RIF dose
Inhalation Treatment
with RIF-loaded
particles
Dose 1 = O x 7 = W
Inhalation Treatment
with RIF-loaded
particles
Dose 2 = W/2
Inhalation Treatment
with RIF-loaded
particles
Dose 2 = W/4
Oral treatment with
free RIF
dose (O) would be
administered daily
per week W=O x 7

*

optional groups depending on previous dual particle systems in vitro
experimentation
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In order to demonstrate improvement over conventional oral treatment against
tuberculosis in terms of patient compliance and drug side effects reduction, the
weekly inhalation doses of RIF loaded GluN-LLA particles for groups 8-to-10 and
11-to-13 would represent ½ and ¼ respectively of the weekly total free RIF orally
administrated to group 14. Groups 5 to 7 would receive same amount of RIF than
group 14 in a week. Thus, group 14 would receive an oral daily dose of 10 mg/kg
of animal of RIF [122] for the entire course of the experiment (two weeks). Mice
on groups 2 to 4, 5 to 7, 8 to 10 and 11 to 13 would be placed in a nose-only
inhalation chamber (ADG Developments, Ltd, Herts, UK) to receive a weekly RIF
dose loaded particles of 0, 70, 35 and 17.5 mg/kg of animal, respectively. SMPGLUN-LLA and MP-GluN-LLA particles with 1:1 RIF-to-polymer mass ratio would
be employed for this experiment. One day after the completion of the two-week
treatment, mice from all groups would be euthanized. Then, lungs and spleen
would be harvested, homogenized and placed in appropriate cell culture medium
for M. tuberculosis loads determination, as explained elsewhere [123,124,126].

Results from this experiment would provide first-hand insight into the in vivo
effectiveness of these particulate systems, and eventually point toward preclinical
and clinical product development phases. Note that reductions of the recovered
bacterial c.f.u. would be expected for all groups administrated with orally or
inhaled RIF, when compared with the no administration of the drug (control
groups 1 to 4). Likewise, any significant reduction, or even similar counting pf
bacteria loads in groups 5 to 13 (inhalation treatment) as compared with group
14 (oral treatment) would be taken as a positive result. As described in table 4.2,
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when compared with oral treatment, RIF loaded particles used via the inhalation
route should improve dosing regimen (less frequency) and groups 8-to-13
decrease the amount of drug delivered to mice. These effects would lead to a
decrease in side effects and improve compliance of the patients.

Others in vivo experiments would be of interest, such as the (3) assessment of
drug concentration in alveolar macrophages, and serum after administration
of the ‘nose-only’ and oral RIF loaded particles [124,126]; and (4) phagocytosis
activity by generation of nitric oxide (NO). These two tests are typically
performed by analyzing the bronchioalveolar lavage (BAL) fluid that can be
collected at several intervals after mice are dosed (only first dose in the treatment
explained above). Parikh et al. [126]collected BAL from animals at intervals of 15,
30, 60, 90, 120, 150, 180, and 240 minutes, which produced important
information about drug uptake and phagocytic stimulation. The procedures to
determine drug concentration in macrophages and NO from BAL fluid are
available elsewhere [124,126].

As previously mentioned, the main advantage of lung delivery through inhalation
therapy is the potential reduction of drug side effects, which is achieved by
decreasing the amount of RIF delivered over the treatment period. This is
possible as a result of avoiding first-pass metabolism and reducing renal
clearance [127]. An adverse effect of RIF and the other first-line anti-tuberculosis
drugs such as isoniazid, pyrazinamide and ethambutol often affects compliance
of the patient [13]. The most serious side effect of RIF is hepatotoxicity, and it
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should be the focus of any future in vivo toxicity studies our group may eventually
desire to pursue. RIF toxicity can be assessed by a (5) study of liver functions
such as serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic
pyruvic transaminase (SGPT) [13,126]. Elevated levels of these enzymes in
serum samples collected from mice groups would serve as indicative of liver
damage. Other valuable set of toxicity tests would be the (6) histological
examination of some organs after treatment, such as lung and liver. In brief,
these tissues would have to be subjected to H&R staining, and then analyzed via
high resolution microscopy [126].

The ability to control side chain lengths (SCL) of the LLA building block in the
GluN-LLA copolymer has been suggested in this dissertation as an important
feature for tuning hydrophobic-hydrophilic characteristics of the particles. Table
4.3 shows four GluN-LLA copolymers with different SCLs that have been
synthesized in the past [1]. Since only GluN-LLA 1:32 has been investigated in
this dissertation with excellent results, the possibility of future experimentation
with formulation naturally arises. The working hypothesis would be that different
SCL should lead to modified RIF-matrix interactions, and as a consequence to
different drug release profiles. As starting point, ultrafine GluN-LLA RIF loading
particles would be prepared using GluN-LLA 1:16, 1:24 and 1:40, and (7) in vitro
drug release determination of new GluN-LLA particulate system would be
performed. Results from this experiment would confirm the conclusions
presented in this dissertation with regard to the mechanism of drug-matrix
interaction, or provide new valuable information.
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Table 4.3. Different molar ratios of LLA grafted glucosamine (GluN-LLA)
GluN-LLA type

Average Molecular

SCL

Weight, Mn (H NMR)
1:16

1800

6.3

1:24

2000

8.7

1:32

3100

10.8

1:40

3700

12.2
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This dissertation has shown the possibility of producing an ultrafine GluN-LLA
particle system as encapsulant for sustained release of RIF for more than 14
days. These biodegradable particles showed biocompatibility and high
endocytosis by macrophages, which are crucial characteristics for proposing new
approaches to treat tuberculosis. However, the subject system proposes the
intracellular killing of M. tuberculosis using RIF alone. In the conventional 6month treatment of tuberculosis, multidrug therapy is necessary to not only cure
patients, but also to prevent the appearance of drug resistance strains. The
World Health Organization (WHO) strongly recommends the use of multidrug
treatments since monotherapy (use of a single drug) is one of the causes of the
MDR-tuberculosis spreading [9]. For this reason, it is reasonable to propose as
future work the following: (7) encapsulation of Ethambutol, Isoniazid and
Streptomycin and (8) in vitro evaluation of multidrug systems on M.
smegmatis. As it can be seen in Figure 4.1, streptomycin possesses an
important number of –OH groups that could produce the hydrogen interaction
needed to yield a strong drug-GluN-LLA interaction, with a concomitant slowing
of the drug release kinetics for this particulate system.
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Figure 4.1. First line anti-tuberculosis drugs
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